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Introduction: Plasma kallikrein (PK) is a cofactor in blood coagulation and
modulates inflammation through the release of E~~_dX~ID.L~ (BK). Previously it was
believed that plasma prekallikrein (PPK), the precursor of PK and a member of
the serine protease superfamily, was synthesised exclusively by hepatocytes and
secreted into circulation. However, recent studies show that various human
tissues contain PPK mRNA. In this study we sought to determine in which human
tissues PK is expressed.
Methods: Following approval by the Ethics Committee at the University of Natal,
tissue samples from the spinal cord, 13 different regions of the brain, 7 different
blood vessels and various other organs were collected at autopsy within 24h of
death (n =10). Sections were probed using polyclonal antibodies specific for PK.
PK concentrations in extracts of these tissues were measured by competitive
EllSA.
Results: A Western blot analysis demonstrated the monospecificity of the
antibody for the PK protein. The presence of immunoreactive PK in cells of the
pancreatic islets of Langerhans served as a positive control for each
immunolabeling experiment. The hepatocytes, renal distal convoluted tubules
and epithelial cells lining the bronchiole and pulmonary alveoli labeled positively
for PK. In the gastrointestinal tract tissue, immunoreactive PK was visualised in
the acinar cells of the salivary gland, in stromal and glandular duct cells of the
X1ll
oesophagus, and in some chief and glandular cells in the stomach. Some of the
above-mentioned tissues contained a few inflammatory cells which stained
intensely for PK.
Immunoreactive PK was visualised in the endothelial cells and smooth muscle
cells of the all the blood vessels examined, except the renal vein. Increased
immunolabeling for PK in the endothelial cells, foam cells and macrophages was
observed in arteries with atheromatous plaques.
In neural tissue immunoreactive PK was observed in neurons, ependymal cells,
fibre tracts, and in secretory cells of the anterior pituitary gland. Immunolabeling
for PK was visualised in some neurons of the spinal cord and in different brain
regions viz. hypothalamus, cerebral cortex, thalamus, brain stem and
hippocampus. In sections of the hypothalamus and spinal cord, we observed
immunolabeling for PK in ependymal cells lining the third ventricle and central
canal respectively. Positive labeling for PK was evident in fibre tracts of the pons,
medulla and hippocampus. No immunoreactive PK was visualised in the choroid
plexus or cerebellum.
High amounts of PK were measured by competitive ELlSA in extracts of the
pancreas (12.94 ± 2.04 /-lg/ml), the pons (1.67 ± 1.46 /-lg/ml) and aorta (0.44 ±
0.14 /-lg/ml). The basilar artery (0.09 ± 0.07 /-lg/ml) and spinal cord (0.09 ± 0.04
/-lg/ml) had the least PK concentrations.
xiv
Discussion and Conclusions: We have shown that the PPK mRNA
demonstrated in various human tissues is most likely translated into protein by
the immunolocalisation of PK within specific cells in the different tissues
examined. The actions of PK within these tissues may be two fold, firstly by its
kininogenase activity it may release BK from high molecular weight kininogen, or
alternatively, PK may act as a proteolytic enzyme on other proteins. With respect
to the latter) PK may be involved in the processing of protein precursors, for
example precursors of the digestive enzymes found in saliva and in gastric
secretion, insulin precursors in the pancreas, and hormonal precursors in the
pituitary gland. The localisation of PK and B1 and B2 kinin receptors in the
kidney, lung, stomach, blood vessels and brain suggests that the effects of PK in
these tissues are mediated by BK-receptor interaction. These may include the
regulation of glucose uptake in the pancreas, water and ion transport in the
kidney, and local and systemic blood pressure in the cardiovascular system. The
presence of immunoreactive PK in neurons suggests that BK-receptor mediated
interaction may regulate neurophysiological processes such as synaptic
transmission. Immunolabeling for PK in polymorphonuclear leukocytes observed




1. The Kallikrein-Kinin System
1.1 Historical Overview
1.1.1 The discovery of kallikrein
In 1926, while undertaking research at the City Surgical Hospital in Munich,
Frey and Kraut noted a considerable reduction in blood pressure when they
injected human or animal urine into dogs. This effect was attributed to a
specific substance designated F-substance, which was isolated from human
urine and from the pancreas and other glandular tissues (Frey and Kraut,
1926). F-substance was later re-named kallikrein after a Greek synonym for
the pancreas, since it existed in that organ in such a high concentration, that it
was originally thought to be produced primarily in this gland (Kraut et al.,
1930). Urine from patients with postoperative reflex anuria was found to
contain very high concentrations of F-substance. When Frey injected such
urine into dog, it failed to produce any effect on the blood pressure suggesting
the presence of a kallikrein inactivator. However it was soon discovered that
the F-substance had been inactivated due to contamination of the urine from
anuric patients' blood, and this principle was referred to as a serum inactivator
of kallikrein (Kraut et al., 1928).
1.1.2 The discovery of kallidin (Lys-BK)
In 1936, Werle was convinced that he was dealing with an enzyme during the
course of his research with kallikrein, but the physiological importance of the
enzyme was still unclear (Werle, 1936). He found that kallikrein preparations
from human urine elicited contractions in isolated dog intestine. The kallikrein
had been shown to possess two activities: induction of hypotension in vivo,
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and contraction of isolated intestinal smooth muscle in vitro. In the course of
his experiments, Werle discovered that kallikrein alone did not contract the
intestine, but, rather, it had to be mixed with serum before spasmogenic
activity was observed in vitro (Werle, 1936). Thus the possible de novo
formation of an active substance in serum-treated kallikrein had to be
considered. The pharmacological actions of this substance were the same as
those of kallikrein. Furthermore, this low molecular weight thermostable
substance could be concentrated. The substance, which was thought to be a
peptide, was not a split product of kallikrein but, rather, was derived from a
serum protein. It was named substance OK from the German
darmkontrahierenderstoff (intestine-contracting substance) (Werle et al.,
1937). Shortly thereafter, in 1948, substance OK was renamed kallidin (KO)
and its precursor was named kallidinogen. Owing to the fact that substance
OK migrated in a broad pH range toward the cathode, it was established that
basic amino acids were present in its composition (Werle and Daurner, 1940).
1.1.3 The discovery of bradykinin release by snake venom
The venom of Bothrops jararaca, an extremely poisonous snake occurring
only in South America, was long known to cause vascular shock in the dog
and other species, including man. A sample of the venom was brought to the
Instituto Biol6gico in Sao Paulo, Brazil, where studies were performed to
determine the role of the venom in releasing histamine, and to examine the
mechanisms underlying venom-induced vascular shock. The assumption that
the effects of B. jararaca venom were mediated by histamine was based on
earlier work by Feldberg and Kellaway (1938) who had demonstrated the
release of histamine by the venom of many Australasian snakes. When blood
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incubated with B. jararaca venom was applied to guinea-pig ileum suspended
in Tyrode's solution containing an anti-histamine and atropine, it surprisingly
had a stimulating effect on the isolated smooth muscle. This effect was not
due to the direct action of the venom, since the preparation had previously
been made refractory to it. No desensitisation was observed after several
additions of serum to the bath containing guinea-pig ileum. The contractions
produced by the active peptide were slow in nature and exhibited a short
latent interval when compared to those induced by histamine and
acetylcholine. Rocha e Silva and collaborators (1949) coined a name from
Greek for this substance, using the word kinin (indicating movement) with the
prefix brady (indicating slow) to describe the slow effect of the substance on
the guinea-pig ileum. Thus the new substance was termed bradykinin (BK).
BK was found to be thermostable, dialysable through cellophane, resistant to
prolonged boiling in 0.1-1.0 N Hel solution, but rapidly destroyed if heated in
alkaline solution (Rocha e Silva et al., 1949). Significantly, in the seminal
publications by Rocha e Silva and Beraldo (1949), these authors associated
the actions of BK with the discipline of autopharmacology. This term was
introduced to indicate the important phenomenon of endogenous chemical
mediation of physiological and pathophysiological events in the body.
1.2 General Overview
Kallikreins are a group of serine proteases found in glandular cells, some
body tissues, biological fluids and neutrophils (Bhoola et al., 1992). Tissue
kallikrein (TK) and plasma kallikrein (PK) are the two main types of kallikrein
found in humans. PK occurs in zymogen form and differs significantly from TK
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in its synthesis, localisation, biochemical, immunological and functional
characteristics.
1.2.1 Tissue kallikrein
TK is the serine protease product of a family of 3 genes in humans, up to 20
genes in rat, and 24 genes in mouse. All TK genes, regardless of species,
contain 5 exons and 4 introns (Margolius, 1996). The human genes, clustered
on chromosome 19 at q13.2-13.4 is designated hKLK1 and found to be
expressed in pancreatic and salivary gland duct cells as well as kidney and
intestine (Margolius, 1996). The human neutrophil contains TK mRNA,
indicating that expression can occur in these cells (Naidoo et al., 1999b). The
closely related hKLK3 gene is of interest because it is only expressed in
prostate and codes for the prostate-specific antigen, a serine protease with
high sequence homology to TK. The hKLK2 gene is also only expressed in
prostate but the function of its product remains unknown.
True human TK is an acidic glycoprotein of 24-45 kDa (Margolius, 1996).
Most of the variation in molecular weight is due to variable glycosylation; for
example human urinary kallikrein has -20% carbohydrate (Margolius, 1996).
The purified renal enzyme is synthesised as a zymogen called prokallikrein. It
has a 17 amino acid signal peptide preceding a 7-amino acid activation
sequence, which must be cleaved to produce the active enzyme (Margolius,
1996). Several proteases, including a human renal thiol protease, are capable
of activating prokallikrein (Figure 1.1). Once activated, TK cleaves low




































































































































Figure 1.1 OVERVIEW OF THE TISSUE AND PLASMA KALLIKREIN-KININ
SYSTEMS
TK and PK are the two protagonists of the kinin system. Tissue prokallikrein,
kininogen (~K) to form kallidin. Plasma prekallikrein is activated by the intrinsic
contact system to PK where it acts upon high molecular weight kininogen (HK)
upon activation by proteases and trauma, acts upon low molecular weight
to release bradykinin (BK). The action of carboxypeptidases upon kallidin and
BK releases the peptides desArg1°-kallidin and desArg9-BK respectively.
Angiotensin )converting: enzyme (ACE) inactivates the carboxypeptidase
cleavage products as well as BK. The Iys residue of kallidin can be cleaved by
aminopeptidase to form 'BK.
Ser COOH-terminal bond to release Lys-BK (kallidin) (Figure 1.1). Conversion
of Lys-BK to BK can occur via the action of aminopeptidases and since these
peptides are not equipotent, such conversion is physiologically important.
Several inhibitors of the enzymatic activity of TK are known, including
aprotinin, the bovine basic pancreatic trypsin inhibitor (a 6.5 kDa, 58-amino
acid polypeptide) and a new serine protease inhibitor (a serpin) called
kallistatin (Margolius, 1996). Aprotinin is widely used experimentally as a TK
inhibitor even though it is not specific since it is capable of efficiently inhibiting
other serine proteases. Kallistatin, a 58 kDa acidic protein, slowly forms heat-
stable complexes with active TK (and other serine proteases) that can be
blocked by heparin (Zhou et al., 1992). Although the protein is measurable in
human plasma, its actual target in vivo and its role in regulating kallikrein
activity has still to be elucidated.
1.2.2 Plasma kallikrein
1.2.2.1 Synthesis and circulation ofPK
Plasma prekallikrein (PPK) is synthesised in the liver and secreted into blood
as a single polypeptide with a molecular weight of 88 kDa (Mandle and
Kaplan, 1977; Bouma et al., 1980). It is present in plasma ata concentration
of 35-45 Jlg/ml and circulates as a covalent complex with high molecular
weight kininogen (HK) (Mandle et al., 1976). Approximately 75% of the
zymogen PPK circulates in plasma as a heterodimer complex with HK, while
the remaining 25% circulates in a free form. Recent evidence suggests that
the complex is attached to the external surface of the neutrophil membrane
through binding sites on domains 3 and 5 of HK (Henderson et al., 1992;
7
Figueroa et al., 1992a). The neutrophil thereby provides a circulating platform
for the HK-PPK complex.
1.2.2.2 Activation ofPK
PK is activated by cleavage of an internal peptide bond in PPK by either
activated clotting Factor XII (Factor Xlla) or Factor XII fragments. This
cleavage results in the formation of one heavy chain (55 kDa), and a light
chain (33 kDa) linked by disulphide bridges. The active site (catalytic domain)
of PK is associated with the light chain of the molecule (Mandle and Kaplan,
1977). The heavy chain, with four large amino acid sequence repeats,
contains the binding site for HK, and is required for the surface-dependent
pro-coagulant activity of PK (van der Graaf et al., 1982). Apart from protecting
activated PK from its inhibitors, the PK-HK complex (in conjunction with
Factor XII) is involved in the activation of the complement system.
Furthermore, this complex plays an important role in the surface-dependent
activation of Factor XII that results in coagulation of blood, formation of kinins,
regulation of vascular tone and fibrinolysis. Once the cascade is triggered,
clotting occurs to initiate thrombus formation together with the formation of PK
and the release of kinins on endothelial and subendothelial surfaces.
1.2.2.3 Substrates and functions ofPK
Substrates for PK include HK, LK, prorenin and Factor XII. HK is the preferred
physiological substrate for PK, which releases BK from HK by hydrolysis of
Lys-Arg and Arg-Ser bonds to yield the nonapeptide with arginine at both
amino and carboxyl terminals (Figure 1.1). Despite LK being a poor substrate
for PK, PK can form BK upon cleavage of LK in the presence of neutrophils.
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This is possible because neutrophil elastase cleaves a fragment from LK from
which PK readily releases BK. This reaction possibly occurs in vivo for kinin
generation from LK. This activity has important implications because LK has
been localised on the external membrane of the neutrophil (Figueroa et al.,
1992a).
PK has a significant effect on polymorphonuclear (PMN) leukocytes, and is
therefore considered to play an important role in inflammation. PK shows
chemotactic activity for PMN leukocytes (Kaplan et al., 1972). Purified PK also
results in marked aggregation of these cells with a similar potency to the
chemotactic peptide, N-formyl-L-methionyl-L-Ieucyl-L-phenylalanine (N-fMLP)
(Schapira et al., 1982). These effects seem to be attributable exclusively to
active PK, since PPK or PK preincubated with soybean trypsin inhibitor (SBTI)
appeared to be ineffective.
1.2.2.4 Molecular structure
A single gene codes for PPK, which is synthesised in the liver and secreted
into blood as an inactive molecule (Bhoola et al., 1992). PPK is a single chain
glycoprotein with an isoelectric point of 8.9 and exists in two forms of 85 and
88 kDa in plasma (Mandel and Kaplan, 1977). The mature human enzyme is
made up of 619 amino acids with 371 amino acids at the amino terminus
linked to a catalytic chain of 248 residues (Bhoola et al., 1992). Hydrolysis of
a single Arg-lIe bond (in positions 371 and 372) results in the formation of a
two-chain protease molecule held together by a disulphide bond (Seidah et
al., 1988). Both molecular forms are cleaved by Factor Xlla in a manner that
results in the heavy chain being linked through the disulphide bridge to a light
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chain of two different molecular weights, which is dependent on the initial
molecular form involved (Bouma et al., 1980).
The heavy chain comprises four domains arranged in sequential tandems of
90 and 91 residues (Bhoola et al., 1992). Each of the four domains is bridged
by six half-cysteine residues, except the last one which carries two additional
half-cysteine residues to link the heavy and light chains together. The amino
acid sequences of the repeat segments show considerable homology with
Factor XI (Chung et al., 1986). The active site of the enzyme resides in the
light chain in a catalytic triad consisting of His415, Asp464 and Ser59 (Mandel
and Kaplan, 1977; van der Graaf et al., 1982). An aspartate at position 559
provides specificity for substrate binding and the preferential cleavage of the
C-terminus of basic amino acids.
The serine proteases, like PK, involved in blood coagulation and fibrinolysis,
differ from the digestive proteases in that they have large non-catalytic
segments present in the N-terminal regions of their molecules. These non-
catalytic segments serve to mediate the binding of these proteases to their
zymogens, to other proteins or surfaces and, through these interactions,
determine the location and substrate specificity of these enzymes (Chung et
al., 1986). Also, these non-catalytic segments, which have been referred to as
regulatory regions, are often organised into recognisable domains (Patlhy,
1985). Five types of domains have been identified, including kringle domains,
vitamin K-dependent calcium binding domains, growth factor domains, and
type I and type 11 domains of fibronectin (Fung et al., 1985; McMullen and
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Fujikawa, 1985; Foster and Davie, 1984). These domains, including the
kringle domain and type I and type 11 fibronectin domains, are also present in
other proteins (Gray et al., 1983). This indicates that these domains have
evolved in genes other than those of the serine protease family, and have
been transferred and fused to the serine protease domain during evolution by
some translocational event.
The four tandem repeats that constitute the heavy chain of PK define a new
type of domain that has yet to be observed in other proteases except for
Factor XI (Fujikawa et al., 1986). These tandem repeats are essential for the
coagulant activity and neutrophil aggregation induced by PK (van der Graaf et
al., 1982; Schapira et al., 1982). Cleavage of the heavy chain of PK by an
unidentified protease(s) in acetone-activated plasma produces a modified
form of PK, designated B-kallikrein (Chung et al., 1986). This enzyme shows
reduced activity in the cleavage of HK and fails to elicit neutrophil aggregation
and elastase release (Colman et al., 1985). The contribution of the heavy
chain to coagulant activity can be attributed to the specific binding of the
heavy chain to HK. This interaction is required prior to the proteolytic
conversion of HK to an activated form that is composed of an N-terminal
heavy chain and a C-terminallight chain (Chung et al., 1986). This proteolytic
modification of HK is associated with the expression of enhanced coagulant
cofactor activity (Scott et al., 1984). The role of the heavy chain in neutrophil
aggregation is unclear. It is suggested that the heavy chain might bind to
neutrophil membrane receptors and that such binding is required prior to the
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induction of the kallikrein proteolytic activity that leads to neutrophil
aggregation and elastase release (Colman et al., 1985).
An analysis of the degree of homology among the four repeats in PPK
indicates that repeats 1 and 3, and repeats 2 and 4, share the highest degree
of homology (Chung et al., 1986). This suggests that the time of divergence of
repeat 3 from repeat 1, and repeat 4 from repeat 2, may be similar. This
pattern of similarity is consistent with the proposal that the four tandem
repeats in the heavy chain of PK resulted from two gene duplication events in
which a single primordial repeat element was initially duplicated to give rise to
two tandem repeats (Chung et al., 1986). Subsequently, the entire locus
containing the two contiguous repeats was duplicated to give rise to the
present four tandem repeats (Chung et al., 1986). PPK shows a high degree
of identity (58%) with Factor XI, which also contains four homologous tandem
repeats in the amino terminus of the molecule (Fujikawa et al., 1986). The
high degree of identity between these two proteins extends beyond the
tandem repeats into the catalytic domain which suggests that the genes for
these two proteins are closely related and have recently diverged from a
common precursor. Homology alignments of the catalytic light chain of PK
with the corresponding chains of other serine proteases indicate that the light
chain of PK is closely related to those of Factor IX, Factor XII, protein C, and
more distantly related to those of plasmin, urokinase, pancreatic kallikrein,
and tissue plasminogen activator (Chung et al., 1986). The fact that the heavy
chain of PPK has no structural similarity with these serine proteases suggests
that the primordial gene for PPK and Factor IX has probably diverged from a
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common ancestor of Factor IX through a recombination event(s) that fused
the catalytic chain to the heavy chain repeat elements.
1.2.3 Kininogens
Kininogens are the substrates for kallikreins. Two main types of kininogens
exist in humans: high molecular weight kininogen (HK) and low molecular
weight kininogen (LK). A third, T-kininogen, has been found only in rats. The
single human kininogen gene (K) is localised to chromosome 3q26-qter close
to two related genes, the a-2-HS glycoprotein and the histidine-rich
glycoprotein (Margolius, 1996). It codes for the production of both HK (626
amino acids; 88-120 kDa) and LK (409 amino acids, 50-68 kDa) via
alternative splicing from 11 exons spread over a span of 27 000 base pairs
(Kitamura et al., 1985). The 9 exons upstream of the kinin sequence code for
the same amino acids in both kininogens; the portion of exon 10 downstream
of the kinin is unique to HK mRNA, whereas exon 11 is expressed only in LK
mRNA (Margolius, 1996). The kininogen receptor is formed by a complex of
three proteins: gC1 qR, suPAR, and cytokeratin 1 (Schmaier, 1997).
All kininogens are single-chain glycoproteins composed of a N-terminal heavy
chain, a smaller variable C-terminal light chain and the kinin moiety
intervening (Figure 1.2) (Margolius, 1996). Multiple disulphide bridges are
present in both HK and LK. Separate functions are known for each of the
molecules, including inhibition of cysteine proteases such as cathepsins and
calpains by the heavy chains, binding to endothelial surfaces and promotion
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Figure 1.2 THE DOMAIN STRUCTURE OF HIGH MOLECULAR WEIGHT
KININOGEN
HK is divided into 3 regions: a heavy chain consisting of domains D1-3; the
bradykinin region- domain D4; and a light chain consisting of domains D5 and
D6. D1 binds calcium. D 2, a cysteine protease inhibitory region, particularly
antagonistic to the actions of calpain. D3 which also comprises a cysteine
protease inhibitory region, contains a major cell-binding site. D4 which
contains BK, has an amino terminal end that has a-thrombin inhibitory activity
and a carboxyl terminal that has cell-binding properties. D5 is the major cell-
binding site and it also contains the artificial surface-binding site. Its positive
charges facilitate interaction with anionic surfaces. D6 is the plasma
prekallikrein and Factor XI binding sites. Note the cleavage sites on HK where
plasma kallikrein acts to release bradykinin.
binding of various kinin receptors by kinins released from the molecules by
the proteolytic kallikreins (Margolius, 1996).
The cardiovascular system is presented with kininogens that are synthesised
primarily in the liver (Nakanishi, 1987), and then secreted and transported in
plasma as well as on platelet and neutrophil cell membranes (Schmaier et al.,
1983; Gustafson et al., 1989). Both HK and LK occupy high affinity binding
sites on the unstimulated platelet , presumably forming a ready reservoir for
kinin release after proteolysis. In addition, human vascular endothelial cells
contain mRNA for HK (Schmaier et al., 1988). BK upregulates the expression
of kininogen binding sites on the surface of human vascular endothelial cells
(Zini et al., 1993). Because such binding protects:at least HK from proteolytic
cleavage from kallikreins, kinin-induced upregulation may serve to attenuate
kinin generation at sites of vascular injury. It may also be possible that
regulation of the kininogen gene expression affects systemic blood pressure
regulation (Schmaier, 1992).
1.3 PK inhibitors
Guinea-pig plasma enhances vascular permeability when injected into guinea-
pig skin, but because this effect is short lived it led to the search for a
kallikrein inhibitor in guinea-pig plasma. The circulating inhibitors of kallikrein
in plasma, first described by Werle, Kraut and colleagues were low molecular
weight proteins (Heimburger et al., 1971) isolated from bovine organs (Kraut
et al., 1928; Werle, 1934). Higher molecular weight inhibitors of PK isolated
from plasma occlude or combine with the catalytic site of the kallikreins.
These include a2-macroglobulin, C1 inhibitor and antithrombin III for PK
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(Ratnoff et al., 1969; Vahtera and Hamberg, 1976), and u1-antitrypsin for TK
(Geiger et al., 1981). u2-macroglobulin and u1-antitrypsin occur at the highest
concentration in plasma (Heimburger et al., 1971). C1 inhibitor combines with
PK to form an inactive complex. u2-macroglobulin also forms a complex with
PK, suppressing approximately 75% of its functional activity. Antithrombin III
is a minor inhibitor of PK.
PK can be rapidly inactivated by C1 inhibitor, which also has the capacity to
inhibit Factor XII with high affinity (Cameron et al., 1989). Further inhibition
could occur with u2-macroglobulin, antithrombin Ill, and mutant U1-
antitrypsins. After the PK-inhibitor complexes are formed, they are rapidly
cleared from the circulation. It has been proposed that the combination of both
PK (Schapira et al., 1982) and Factor Xla (Scott et al., 1982) with HK protects
the former from inhibition by C1 inhibitor, u2-macroglobulin and u1-antitrypsin,
thereby augmenting the plasma half life of the enzyme.
Kallikrein inhibitor proteins inhibit trypsin and elastase but not chymotrypsin. It
has an inhibitory spectrum that is similar to that of contrapsin in mouse
plasma (Imamura and Kambara, 1989). In pathological states such as
hereditary angioedema (HAE) (Landerman et al., 1962) and inflammatory joint
disease, activation of PK and/or the complement system (C2) is believed to
be responsible for the symptoms that patients experience. The clinical state in
HAE (an autosomal disorder arising from a reduction in both the amount and
efficiency of C1 inhibitor) is characterised by localised swellings, laryngeal
oedema, and abdominal pain. Some studies support a complement C2-
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dependent mechanism, but most report BK to be the primary inflammatory
mediator formed in HAE, because during the swelling attacks concomitant
with the formation of BK, there is a reduction in the circulating levels of
prekallikrein and HK. Active PK has been detected in suction-induced blister
fluids obtained from patients with HAE (Curd et al., 1980). Of particular
interest has been the finding that only during pregnancy did the plasma of a
patient with HAE show sustained contact activation which resulted in the
formation of kalukreln-ce-macroqlobulln and kallikrein-50 kDa HK complexes.
These disappeared after delivery, with the subsequent return of the intact 120
kDa HK molecule (Chibber et al., 1989). Replacement therapy with C1
inhibitor during attacks of swelling and oedema produced clinical improvement
that was associated with an increase in circulating levels of HK (Kodama et
al., 1984). Another clinical condition in which cascade-formed kinins are
considered to be involved, is the cutaneous late phase reaction. This reaction
is immunoglobulin E (lgE)-dependent and is caused by the secretion of
mediators from activated mast cells. In the early phase of the reaction when
wheals and flares occur (appearing within 10 min and disappearing in 60 min),
histamine, substance P, prostanoids, and 5-hydroxytryptamine (5-HT) may be
involved, whereas during the late phase, there is strong evidence for a
contribution by kinins (Kaplan et al., 1989).
1.3.1 et esterase inhibitor
Serpin, a serine protease inhibitor of C1, is a single chain polypeptide with a
molecular weight of 104 kDa, which is cleaved when it interacts with PK or
plasmin (Heimburger et al., 1971; Harpel et al., 1975). However, the formation
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of a reversible complex between PK and HK decreases the rate of inactivation
of C1 inhibitor (Schapira et al., 1981).
Factors Xlla, Xla, kallikrein and C1 protease are highly regulated by C1
inhibitor which is the only serpin known to inactivate C1 sand C1 r, and also
contribute to over 90% of the plasma's capacity to inhibit Factor Xlla (De
Agostini et al., 1984). C1 inhibitor contributes most of the plasma capacity to
inhibit kallikrein (Schapira et al., 1981). The regulation of Factor Xla is
achieved by Factor Xla forming a complex with the inhibitor (Scott et al.,
1982). The primary inhibitor of Factor Xla regulation is u1-proteinase inhibitor
(U1 -PI), with u2-antiplasmin (u2-APO) and antithrombin III (AT-Ill) having less
potent inhibitory roles. It is clear that sustained activation of the contact and
complement systems, which can lead to the depletion of C1 inhibitor, will
result in reduced inhibitory regulation of PK and Factor Xlla (Pixley and
Colman, 1997). This decrease in the regulatory molecule allows the reciprocal
activation to proceed between these two enzymes, which results in sustained
release of BK and neutrophil activation (Pixley and Colman, 1997). Continued
depletion of C1 inhibitor can also stimulate the complement system by leaving
C1r and C1s unchecked, thereby allowing formation of a membrane attack
complex (MAC) with ensuing cell lysis. It is interesting that C1 inhibitor has not
been demonstrated to regulate proteases other that Factor Xlla, kallikrein and
Factor Xla, generated in the intrinsic or extrinsic coagulation cascades. This
suggests that low levels of C1 inhibitor may favour activation of the kallikrein-
kinin system (KKS) in the absence of appreciable coagulation. In shock,
where organ perfusion is reduced, a local environment exists in which C1
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inhibitor is depleted and not further supplied from blood (Pixley and Colman,
1997). Thus, both the kinin and complement systems may be fully activated
and uncontrolled, thereby further exacerbating inflammation.
1.3.2 a2-Macroglobulin
o.2-macroglobulin contributes to 58% of the regulatory activity of kallikrein. The
formation of kallikrein:o.2-macroglobulin complexes were monitored by
developing an assay for contact activation in blood samples obtained from
patients and primates with systemic inflammatory response syndrome (SIRS)
(Pixley et al., 1995). o.2-macroglobulin has a molecular weight of 725 kDa
(Jones et al., 1972; Hall and Roberts, 1978), is denatured below pH 4.0
(Barrett, 1981) and has an isoelectric point of 5-5.2 (Barrett et al., 1979). Its
defined inhibitory characteristics are: (i) it specifically traps proteases, (ii) it
covalently links proteases and other molecules that follow into this trap, and
(iii) it participates in a non-covalent, non-steric adherence reaction with a
variety of molecules unrelated to their proteolytic activity for example thrombin
(Starkey and Barrett, 1977). It has been speculated that each subunit of 0.2-
macroglobulin has a region which is highly susceptible to limited proteolysis,
and when bound by proteases, causes a conformational change in the 0.2-
macroglobulin molecule, allowing it to trap the protease molecule within itself
(Barrett, 1981). After the molecule is trapped, a barrier is formed at the
opening which allows the entry of particles less than 10 kDa in size to pass
through into the active site domain of o.2-macroglobulin. The largest trappable
known enzymes are PK and plasmin. In this complex, the active centre
remains accessible to small molecules (Haverback et al., 1962) and as a
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consequence the enzymes retain their ability to act on small synthetic
substrates in the presence of the PK inhibitors. When PK or plasmin interacts
with u2-macroglobulin, the inhibitor undergoes cleavage (Harpel et al., 1975)
similar to a reaction occuring between neutrophil proteases and U2-
macroglobulin or antithrombin III (Movat et al., 1976).
1.3.3 Antithrombin 11/
Antithrombin Ill, an inhibitor of thrombin (8teinbuch et al., 1968), has a
molecular weight of 63-65 kDa, an isoelectric point of 5.1 (Burrowes and
Movat, 1977) and forms a complex with PK resulting in a molecule that ranges
from 110-139 kDa in size (Vennerod et al., 1976).
1.3.4 Heparin
Heparin is a catalytic cofactor that significantly accelerates the action of
antithrombin III to inactivate Factor Xa and thrombin (Reddigari et al., 1997). It
contains a specific sulphated carbohydrate sequence that facilitates its
binding to antithrombin Ill, resulting in a conformational change in the
structure of the inhi.bitor to form a more efficient enzyme inactivator. However,
heparin does not appreciably accelerate the inhibition of PK by antithrombin
Ill.
1.3.5 Soybean trypsin inhibitor (SBTI)
8BTI is a double-headed inhibitor of proteases which has a configuration
specific for the inhibition of trypsin-like enzymes. It has a molecular weight of




Vasoactive peptides, like kinins, exert their actions by binding to specific high-
affinity receptors located in the cell membrane of target cells. After
occupancy, receptors undergo rapid phosphorylation, redistribution in the
plane of the membrane, and endocytosis. The receptor-ligand interaction
promotes signal transduction mechanisms in the cell membrane and cytosol
which involve the activation of ion channels or enzymes to modulate the level
of second messengers such as cyclic nucleotides, phosphoinositides and
C 2+a .
The two main receptor subtypes for kinins viz. 81 and 82 have been
characterised and cloned. The 81 receptor shows some, but limited,
homology to the 82 receptor. The cloned 82 (McEachern et al., 1991) and 81
receptors (Hess et al., 1994) belong to the superfamily of G protein receptors.
They have seven characteristic membrane-spanning regions linked by three
extracellular and four intracellular loop regions that are unique in their
sequences (McEachern et al., 1991). Most of the actions of 8K and kallidin
are, however, mediated by the activation of the 82 receptor. These effects
include vascular smooth muscle relaxation, endothelial cell retraction,
contraction of visceral and bronchial smooth muscle, and activation of
peripheral afferent C-type nerve fibres (Riccioppo Neto et al., 1974; Rehbock
et al., 1994). 82 receptor activation may stimulate the inositol triphosphate
pathway via phospholipase C and/or the arachidonic pathway via
phospolipase A2 (8urch and Axelrod, 1987). The human 82 gene maps to
chromosome 14 (Powell et al., 1993). 82 receptor mRNA is present in human
kidney (highest level), pancreas, colon, salivary gland, prostate, uterus,
21
skeletal muscle, adrenal glands, stomach, breast, ovary, brain, heart, arteries,
veins and lung (Hess et al., 1992; Ma et al., 1994). The 81 receptor, however,
is induced rather than being constitutively expressed. Expression can be
induced in animals by exposure to low doses of interleukin-1 (IL-1) or
endotoxin. The main endogenous agonist for the 81 receptor is des-Arg
9-8K,
which is a metabolite that results from the hydrolysis of C-terminal arginine of
the kinin moiety by kininase 1-carboxypeptidase N (KI-CPN) (8hoola et al.,
1992; Marceau, 1995). During inflammation, or after exposure of tissue to
lipopolysaccharides, the presence of 81 receptor becomes evident in smooth
muscle cells and fibroblasts.
1.4.1 Kinin receptor antagonists
Replacement of the C-terminal phenylalanine of 8K or kallidi,m by leucine
produces an antagonist that is highly selective for 81 receptors. Replacement
of the Pro7 in 8K (or Pro" in kallidin) by a D-aromatic amino acid, like D-
phenylalanine, yields an effective antagonist that is selective for 82 receptors
in many tissues and species. Although the presence of this D-amino acid
residue impaired the degrading action of kininase II-angiotensin converting
enzyme (KII-ACE), this first generation of 82 antagonists was relatively weak
with half lives of only a few minutes in vivo in rats. The D-Arg residue at the N-
terminus protected them from aminopeptidase degradation. They were,
however, substrates for KI-CPN, which terminated their action on 82
receptors and converted them to 81 antagonists (Regoli et al., 1986). Despite
these limitations, antagonists such as DArg-Arg-Pro-Hyp-Gly-Thi-Ser-DPhe-
Thi-Arg (NPC-349) were critical for demonstration of the participation of kinins
in both normal and pathological conditions.
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The second generation of 82 antagonists came with the introduction of HOE-
140 (DArg-Arg-Pro-Hyp-Gly-Thi-Ser-DTic-Oic-Arg; icatibant) by Hoechst
(Hock et al., 1991; Wirth et al., 1991). The proline-like Oic residue at position
8 made this antagonist resistant to the action of KI-CPN and conferred high
potency and long duration of action in vivo. This antagonist has been used in
human clinical trials with success in allergic rhinitis and allergic asthma
(Akbary et al., 1996; Austin et al., 1994). A different antagonist, 8radycor (CP-
0127)- a dimer of DArg-Arg-Pro-Hyp-Gly-Thi-Cys-DPhe-Leu-Arg in which the
Cys residues were linked by bis-maleimidohexane, was also introduced
(Cheronis et al., 1992). 8radycor has been found to be effective in animal
models of septic shock (Whalley et al., 1992) and in closed head trauma in
humans (Rodell, 1996). Several heterodimers having both 81 and 82
antagonist activity have also been introduced (Cheronis et al., 1994).
A third generation of 8K antagonists was characterised by the introduction of
analogs containing the novel amino acid, a-(2-indanyl)-glycine (Igl) (Stewart
and Gera, 1996). The presence of Igl residue at position 5 of these kinin
receptor antagonists evidently conferred resistance to degradation by the
neutral endopeptidase, enkephalinase, and yielded antagonists that appear to
be resistant to all kininases and show remarkably long activity in vivo.
Combined with a D-lgl residue at position 7, this new antagonist has about the
highest potency known. Dimers of certain of these antagonists are selectively
cytotoxic for cells of small cell lung cancer (SCLC) in vitro and in vivo. As
examples, DArg-Arg-Pro-Hyp-Gly-lgl-Ser-Dlgl-Oic-Arg (89430), an extremely
potent and long-acting antagonist of 81 and 82 receptors, is stable against
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the endogenous kininase enzymes, and is active in various in vivo models,
including intragastric administration (Hanson et al., 1996).
1.5 The biological actions of kinins
BK and kallidin (Lys-BK) are biologically active nona- and deca-peptides
respectively, released upon cleavage of kininogens by kallikreins. These
kinins are the primary mediators produced during inflammation, a regular
biological response to injury. They have the ability to cause vasodilation,
venoconstriction and endothelial cell retraction that result in increased
capillary permeability. By depolarising C-type nerve fibre terminals, they
induce pain. Additionally, the biological actions of kinins include hypotension
and contraction of smooth muscles of the bronchopulmonary tree, intestine
and uterus. Kinins also have the capacity to release neurotransmitters, such
as substance P; stimulate cytokine synthesis such as interleukin-1 and tumour
necrosis factor; induce the formation of prostaglandins and leukotrienes by
activating phospholipase A2; and release endothelium-derived relaxing factor
(EDRF; nitric oxide) from endothelial cells (Bhoola et al., 1992). At a cellular
level, kinins promote glucose and chloride transport, stimulate osteoclasts and
increase DNA synthesis (Bhoola et al., 1992).
1.5.1 Bradykinin
In the KKS, PK generates from HK the nonapeptide BK with the amino acid
sequence Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg. BK induced receptor
stimulation of endothelial cells promotes the synthesis of PGI2 and release of
tissue plasminogen activator. BK acts as a potent vasoactive peptide which
has a number of effects, mostly involving the inflammatory response.
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Although kinins act as potent dilators of arterioles resulting in hypotension
(Mombouli and Vanhoutle, 1992), BK, however, can both contract and relax
smooth muscle. This is dependent on the type of kinin receptor, the type and
potency of kininases present on endothelial cells, and the presence of EDRF
and PgE2 (Regoli and Barabe, 1980). Increased cytosolic calcium causes the
shortening of contractile proteins in endothelial cells, formation of
fenestrations in the walls of microvascular tissue, and the extravasation of
plasma constituents as well as specific cellular elements of blood, which
results in an increase in BK-induced vascular permeability (Oleson, 1987;
Wiemar et al., 1994). Kinins also modulate the interaction between endothelial
cells and cellular elements in blood (Kaplan and Silverberg, 1987).
Many bacteria release enzymes that increase kinin release by either direct
cleavage of kininogen, or indirectly by activation of the prekallikreins to active
kinin-generating enzymes. The increased vascular permeability caused by
kinins produced in this manner appears to be an important factor promoting
the spreading of bacterial infections through tissues (Maeda et al., 1996).
1.5.2 Inactivation of kinins
The turnover of kinins depends both on the rate of formation, as outlined
above, and the rate of destruction by the enzymic action of peptidases
generally called kininases (Erdos, 1989; Erdos, 1990). These circulating and
local enzymes, found in blood and tissues respectively, include the circulating
kininase I-carboxypeptidase N (KI-CPN) and membrane-bound
carboxypeptidase M (KI-CPM) which cleave the C-terminal arginine of BK to
produce the B1 agonist, des-arg9-BK. Other important kininase-II enzymes are
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angiotensin converting enzyme (KII-ACE) and neutral endopeptidases (KII-
NEP) which cleave and transform the kinin molecule into inactive fragments
(Bhoola et a/., 1992). KII-ACE cleaves two internal peptide bonds, producing
completely inactive metabolites. KII-NEP that occurs both in circulation and in
tissues degrade the molecule into even smaller peptide fragments. Additional
kinin-hydrolysing enzymes are prolidase (aminopeptidase P) and two
endopeptidases (kininase A and B). Sequences for the regulatory and
catalytic subunits for most of these enzymes have been ascertained by cDNA
clones. A series of selective enzyme inhibitors (D-L-mercaptoethanol-3-
guanidino-ethylthiopropanoic acid, ethylenediamintetraacetic acid, 0-
phenanthroline for KI-CPN and KI-CPM, captopril for KII-ACE;
phosphoramidon for KII-NEP; and amastin, bestatin, and puromycin for
aminopeptidases) are available for regulating kininase activity (Bhoola et a/.,
1992).
The relative importance of each of the peptidases in controlling kinin levels
varies with species, type of biological fluid, and tissue site of peptide
formation. In humans, circulating levels of kinins are primarily regulated by KI-
CPN but on endothelial surfaces, particularly in the pulmonary vascular bed,
by KII-ACE. In contrast, the most potent kinin-degrading enzyme in rat plasma
is KII-ACE with little contribution from other peptidases (Ishida et et., 1989).
1.5.2.1 KI-CPN
KI-CPN, originally discovered in the Cohn fraction IV of human plasma (Erdos
and Sloane, 1962), is an arginine carboxypeptidase, optimally active at pH 7.4
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with the capacity of being activated by CoCb. This carboxypeptidase is
synthesised by the liver and secreted into the circulation. It accounts for
approximately 90% of the BK-destroying activity in human plasma (Zacest et
al., 1974) and can also become associated with the vascular endothelium
(Palmieri et al., 1986). Although the primary importance of this enzyme in
cleaving kinins within the circulatory system varies between species, it can
also hydrolyse the C-terminal basic amino acid of several biologically active
peptides like enkephalins, anaphylotoxins and fibrinopeptides.
1.5.2.2 KI-CPM
KI-CPM cleaves the C-terminal arginine of BK and Lys-BK, resulting in the
formation of des-Arg9-BK and des-Arg9-Lys-BK. The optimal pH for degrading
both kinins is in the neutral range. KI-CPM has been purified from human
urine and human placental microvilli and its encoding gene has been cloned
from a human placental cDNA library (Skidgel et al., 1984; Skidgel et al.,
1989; Tan et al., 1989). KI-CPM is a 62 kDa metallopeptidase inhibited by
guanidino-ethylmercaptosuccinic acid and activated by cobalt (optimal at pH
5.5) which replaces zinc as a cofactor (Deddish et al., 1989). Structurally, KI-
CPM is a single-chain glycoprotein with 426 amino acids and six asparagine-
linked glycosylation sites (Bhoola et al., 1992).
1.5.2.3 KII-ACE
KII-ACE is a major kininase in most organs because of its wide distribution in
mammals. Based upon its physical properties, enzymatic characteristics and
immunological cross-reactivity, KII-ACE enzymes in different species and
various tissues are quite similar and likely represent the two-domain somatic
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KII-ACE (Skidgel and Erdos, 1993). KII-ACE purified from various human
tissues is a single-chain glycoprotein. Its estimated molecular weight ranges
from 140-170 kDa in SDS-PAGE (Skidgel and Erdos, 1993). KII-ACE is
heavily glycosylated, the human renal enzyme containing approximately 25%
carbohydrate (Weare et al., 1982). The differences are, however, in the
carbohydrate moieties. ·Owing to its high sialic acid content, KII-ACE is
protected from uptake by liver lectins.
Being a zinc metalloenzyme, chelating agents and sulphydral compounds
inhibit KII-ACE by complexing the active site Zn2+ (Erdos, 1979). KII-ACE has
an optimum pH above neutral, and activity drops steeply at acidic pH primarily
due to the dissociation of Zn2+ from histidine in the active centre (Ehlers and
Riordan, 1990). Studies with rabbit lung KII-ACE showed that anion activation
depends on both the structure of the substrate and the pH of the medium
(Ehlers and Riordan, 1990). Accordingly, the substrates were divided into
three classes, BK being class II substrate with a lower activation constant for
Cl' than angiotensin I, a class I substrate. Weare (1982) described two anion-
binding sites in KII-ACE, with one being the primary binding site.
The concentration of Cl' ions in vivo appears to be high enough for KII-ACE to
be fully active in most tissues, although at some sites, Cl" concentrations may
fluctuate sufficiently to regulate KII-ACE activity with some substrates. The Cl'
ion sensitivity of the membrane-bound recombinant KII-ACE showed that the
cr dependence of the Nand C domains was the same as that determined for
the soluble enzyme (Jaspard and Alhenc-Gelas, 1995).
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1.5.2.4 f(11·~f:J'
Neutral endopeptidase (Neprilysin, KII-NEP) is a zinc metallopeptidase with a
single peptide site containing the canonical HEXXH sequence (Erdos and
Skidgel, 1989). The enzyme is a trans-membrane, single-chain protein of 742
amino acids, but in contrast to KII-ACE, is bound via an uncleaved N-terminal
signal peptide (Roy et a/., 1993). It cleaves peptide substrates with a
molecular weight not usually exceeding 3 kDa at the N-termini of hydrophobic
amino acids, and cleaves BK at the Pro7-Phe8 bond (Almenoff et a/., 1981).
KII-NEP is a second kininase 11 that releases the C-terminal Phe8-Arg9 of BK
(Gafford et a/., 1983). Active peptide substrates for KII-NEP include the B-
chain of insulin (Kerr and Kenny, 1974), enkephalins (Schwartz et a/., 1985),
endothelin (Vijayaraghavan et a/., 1990), atrial natriuretic peptide, substance
P and a chemotactic peptide (Erdos and Skidgel, 1989). Sites where KII-NEP
may be an important kininase include the epithelial cells of the respiratory
tract (Dusser et a/., 1988), skeletal muscles (Dragovic et a/., 1996),
neutrophils (Painter et a/., 1988), renal proximal tubules (Ura et a/., 1987) and
possibly human coronary vessels (Graf et a/., 1995).
1.6 PK and haemostasis
1.6.1 Factor XII
Factor XII, an 80 kDa single chain B-globulin, occurs at a concentration of 30
Ilg/ml in blood (Reddigari et a/., 1997). As an initiator of the contact pathway
for intrinsic coagulation, Factor XII undergoes conformational changes upon
binding to negatively charged surfaces (Wachtfogel et a/., 1999). This
conversion of zymogen to active enzyme is termed solid-phase activation.
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Additionally, autoactivation of Factor XII yields a small quantity of Factor XII
fragments, which can also convert PPK to PK. PK then further activates
Factor XII in the presence of HK; the latter activation then proceeds
exponentially (Wachtfogel et al., 1999). In the absence of a negative surface,
Factor XII can also be activated in the fluid phase by either Factor XI or
plasmin. However, these activators are less potent than PK.
Two major forms of activated Factor XII exist: Factor Xlla (80 kDa), consisting
of two disulphide-linked polypeptide chains (52 kDa and 28 kDa), and Factor
Xllf (28 kDa), both of which are derived from the native molecule (Figure 1.3)
(Wachtfogel et al., 1999). Factor Xlla, which initiates the intrinsic coagulation
cascade, arises from the cleavage of a single Arg-Val peptide bond in the
zymogen. This cleavage initiates coagulant activity by exposure of the active
site, which hydrolyses Arg substrates. Factor XII fragments result from further
proteolysis of the Factor Xlla molecule, and mainly contain the catalytic light
chain and a tiny fragment of the heavy chain. The surface binding property of
Factor Xlla resides in its 52 kDa heavy chain, where the amino acid sequence
contains putative collagen binding domains, growth factor regions, and a
structure characterised by multiple disulphide loops (Wachtfogel et al., 1999).
Substrates of Factor Xlla include PPK, Factor XI, HK and Factor VII. Factor
XII fragments are responsible for the non-immunological activation of the
classic complement pathway. C1 inhibitor accounts for 90% of the inhibition of
both Factor Xlla and Factor XII fragments, while antithrombin III is responsible
for inhibiting the remainder of the activity (Wachtfogel et al., 1999). In
conditions where C1 inhibitor is absent or decreased, as in hereditary
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Figure 1.3 STRUCTURE OF FACTOR XII, Xlla, AND Xllf
This figure shows the structure of the zymogen Factor XII and its active
components, Factor Xlla and Xllf. This zymogen has a molecular weight of 80
kDa, whereas the cleaved Factor Xlla (upon exposure of the catalytic active
site) consists of two disulphide-linked polypeptide chains of 52 and 28 kDa.
Factor XII fragments consist solely of the 28 kDa subunit.
52kDa 28kDa





angioedema, antithrombin III becomes the major, but less potent, inhibitor of
Factor Xlla and Factor XII fragments.
1.6.2 Factor XI
Factor XI is a 160 kDa y-globulin composed of two identical polypeptide
chains of 80 kDa each (Reddigari et al., 1997) linked by disulphide bridges
(Wachtfogel et al., 1999). It occurs in plasma at a concentration of only 5
Ilg/ml (Wachtfogel et al., 1999). This protein exhibits a high degree of
homology with PPK suggesting a common ancestral gene. Factor XI is
activated to Factor Xla upon cleavage by Factor Xlla. This results in two
heavy chains, each with a molecular weight of 50 kDa, and two light chains,
with a molecular weight of 30 kDa each (Figure 1.4). The binding region of
Factor XI is found on its heavy chains, while the active site is located on its
light chains. Substrates of Factor Xla include HK, Factor IX and plasminogen
(Wachtfogel et al., 1999). Virtually all of Factor XI forms a complex with HK,
thus protecting itself from its inhibitors. u1-protease inhibitor is the major
inhibitor of Factor XI. In purified systems, antithrombin III inhibits Factor Xla,
but in plasma it is not a significant inhibitor even in the presence of heparin.
1.6.3 High molecular weight kininogen
High molecular weight kininogen (HK) is present in endothelial cells in culture
(Schmaier et al., 1988; van Iwaarden et al., 1988), and in human vascular
smooth muscle (Figueroa et al., 1992a). This endogenous protein is
synthesised by hepatocytes and secreted into the circulation (Kitamura et al.,
1985). It has six domains of which the first three are homologous to cysteine
protease inhibitors (domains 2 and 3 retain their inhibitory activity), a fourth
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Figure 1.4 STRUCTURE OF FACTOR XI AND Xla
This..figure shows the structure of the 160 kDa Factor XI, composed of two
identical 80 kDa polypeptide chains linked by disulphide bridges. Cleavage of
these polypeptide chains by Factor Xlla produces active Factor XI (Factor
XIa) which comprises two 50 kDa heavy chains linked to two 30kDa light
chains by disulphide bridges.
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domain features the BK moiety, and domains 5 and 6 interact with surfaces
and prekallikrein or Factor XI respectively (Kaplan et al., 1997) (Figure 1.2).
HK directly enhances the surface-mediated formation and function of Factor
XII, PPK, and Factor XI so that activation proceeds optimally. Domain D5
contains positively charged histidine residues that facilitate interaction with
anionic surfaces (Wachtfogel et al., 1999). Domain D6 has specific amino acid
sequences that bind either PPK or Factor XI (Tait and Fujikawa, 1987),
thereby transporting these zymogens to the surface for cleavage by Factor
Xlla (Wachtfogel et al., 1999). HK is a profactor which does not effectively
bind to activating surfaces in plasma until it has been cleaved by PK. The
cofactor is destroyed when Factor XI cleaves the light chain of HK. PK splits
HK in a three step sequential manner. The first cleavage produces a nicked
kininogen composed of two disulphide-linked chains (56 and 64 kDa)
(Schmaier et al., 1997). The second cleavage yields BK (which mediates pain,
vasodilation, increased vascular permeability) and an intermediate kinin-free
protein (Schmaier et al., 1997). The final cleavage results in a stable kinin-free
protein composed of two disulphide-linked chains (45 and 64 kDa), and an
additional peptide of 10 kDa (Wachtfogel et al., 1999). Both HK and LK, which
contain the same amino acid sequences in their heavy chain (D1-D3), are
structurally and immunochemically identical to the cysteine protease inhibitors
(Wachtfogel et al., 1999).
Although recognised more than two decades ago as a defect associated with
a prolonged activated partial thromboplastin time (APTT) (Colman et al.,
1975; Saito et al., 1975; Wuepper et al., 1975), the genetic deficiency of HK is
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not associated with bleeding. Although the incidence of homozygous HK
deficiency is rare, recognition of HK deficiency is greatly facilitated by the
detection of a prolonged APTT. The prolonged APTT associated with HK
deficiency may have contributed to the masking of the physiological
importance of HK as an antithrombin, as well as its role in ordering the
assembly and activation of a PK-dependent fibrinolytic pathway on biological
membranes (Schmaier, 1997).
1.6.3.1 Participation of HK in fibrinolysis
In addition to its unique mechanism of antithrombin inhibition, the recognition
of HK deficiency has purported the role of HK in fibrinolysis (Figure 1.5),
although the specific physiological mechanism is unclear (Colman et al.,
1975; Saito et al., 1975). It is known that contact activation can increase total
plasma fibrinolysis (Niewiarowski and Prou-Wartelelle, 1959). Kallikrein,
Factor Xlla and Factor Xla cleave plasminogen directly, albeit much less
efficiently than tissue-type plasminogen activator or urokinase plasminogen
activator (Mandle and Kaplan, 1979). However, PK has been characterised to
be a kinetically favourable activator of single-chain urokinase in vitro (Ichinose
et al., 1986). Recent studies suggest that single-chain urokinase activation by
kallikrein is most likely to occur on the platelet and endothelial cell surface
(Gurewich et al., 1993). In 1998, Motta and colleagues examined the
relationship between prekallikrein assembly on endothelial cells and its
participation in single-chain urokinase activation. When prekallikrein binds to
HK on endothelial cells, the zymogen becomes activated to kallikrein, as




C1 Complement component 1
C1a Complement component 1- activated
C3f Complement component 3- fragment
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complement and fibrinolytic pathways. An activated surface (anionically charged), HK, and
PPK cleavage from activated Factor XII is required for its conversion to PK. PK in turn
This figure shows the interactions of the plasma kallikrein-kinin system with the coagulation,
cleaves activated HK, thus yielding BK. PK also activates neutrophils along with activated
for the conversion of prourokinase to urokinase. Urokinase then activates the conversion of
Factor XII, and fragments of Complement components C3 and C5. PK activation is required
plasminogen to plasmin, thus resulting in fibrinolysis. In the complement pathway, Factor XII
fragrTJ,ents activates C1 which forms C3 and C5 fragments via a cascade mechanism. In the
coagulation reaction, activated Factor XI converts Factor IX to its active form resulting in









































































prekallikrein to kallikrein on gel electrophoresis and the cleavage of HK (Motta
et al., 1998). PPK activation occurs independently of the active forms of
Factor XII, and its activating enzyme is a Ca2+-requiring metalloprotease
rather than a serine protease (Motta et al., 1998). PPK activation on
endothelial cells is kinetically similar to prekallikrein activation by Factor XII on
an artificial surface. These data showed that contact protein assembly on
endothelial cells results in prekallikrein activation in the absence of Factor XII
and an artificial surface (Motta et al., 1998). This assembly of contact proteins
allows for a physiological pathway of contact activation. The degree of PPK
activation is regulated by HK where increasing HK concentrations upregulate
the enzyme that activates cell-bound PPK. Thus, HK regulates PPK
activation, which then liberates more BK from cell-bound HK and removes HK
from the surface to slow PPK activation (Motta et al., 1998). Also, increased
BK increases kininogen binding, which subsequently decreases soluble
kallikrein from cleaving HK to liberate more BK (Zini et al., 1993). The
pathway for PPK activation and BK liberation is, therefore, tightly regulated.
The PPK activation pathway on endothelial cells results in a kinetically
favourable conversion of single-chain urokinase into two-chain urokinase in
an environment where there is a constitutive molar excess secretion of
endothelial cell plasminogen activator, inhibitor-1 (Motta et al., 1998).
Formation of a two-chain urokinase results in a 4.3 fold increase in
plasminogen activation. This system for plasminogen activation occurs in an
environment where there is no tissue plasminogen activator or fibrin, and the
mechanism for single-chain urokinase activation is another pathway for
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cellular fibrinolysis that is either independent of or co-joined with single-chain
urokinase activation associated with its binding to its receptor (Higazi et al.,
1995). This also provides a probable explanation of how two-chain urokinase
can be formed in plasminogen knockout mice (Carmeliet and Collen, 1995).
HK and LK assemble on cell membranes allowing for BK to be liberated in a
protected environment, wherein this potent, vasoactive peptide can activate
its receptors to influence vascular function. Both kininogens participate in
maintaining the constitutive anti-coagulant environment of the intravascular
compartment by virtue of their antithrombin inhibitory activities. This
contributes to the physiology of vasculature by regulating local blood flow,
thrombosis and fibrinolysis.
1.6.4 The Contact Activation Cascade
The plasma kallikrein-contact activation system (PKCS) comprises a cascade
of proteinases which, when activated, generates the nonapeptide, BK, from
HK. There is also cross-activation of C1 protease (the initial protein of the
classical complement pathway), hydrolysis of prourokinases to yield
urokinases (which activates cell-associated fibrinolysis), and activation of
Factor XI of the intrinsic blood coagulation pathway. The PKCS is triggered
following activation of Factor XII by endotoxin (Kalter et al., 1983) and
microbial proteases (Molla et al., 1989) to yield Factor XIJa, or indirectly by
auto-activation through injury to endothelium.
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Factor Xlla cleaves PPK to its active form PK, which can then further activate
more Factor XII to Factor Xlla. HK associated with PPK forms a non-covalent
complex and aids PPK in the feedback activation by carrying it to a common
activating surface where Factor XII or Factor Xlla are present. When the PPK-
HK complex is activated to a PK-HK complex, PK can cleave HK at two sites,
causing the release of BK. BK, via activation of cell surface B2 receptors on
the vascular endothelium, releases nitric oxide and prostacyclin, both potent
vasodilators. Thus activation of the PKCS can contribute significantly to the
hypotension that occurs in sepsis. Factor Xlla also contributes to coagulation
by activating Factor XI to Factor Xla, thereby initiating the intrinsic cascade of
coagulation.
PK can also stimulate neutrophil chemotaxis, aggregation, elastase release,
and oxygen consumption in vitro (Goetzl and Austen, 1974; Schapira et a/.,
1982; Wachtfogel et a/., 1983). Furthermore, neutrophil activation in vivo,
assessed by increased complexes in plasma between human neutrophil
elastase (HNE) and Cx.1-proteinase inhibitor (u1-PI), occurs in sepsis and is
associated with a poor prognosis (Egbring et a/., 1977; Duswald et a/., 1985;
Nuijens et a/., 1992). Thus the KKS may contribute to HNE-mediated tissue
damage seen in sepsis.
1.6.5 Regulation of Contact Activation
The auto-activation of Factor XII is very slow. However, the reciprocal
reactions involving kallikrein contribute to the rapid activation of Factor XII.
The in vivo source of this active enzyme is unknown, but may be formed by
other plasma proteases, like plasmin or activation along cell surfaces. In fact,
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very slow turnover of the cascade may always be occurring (Silverberg and
Kaplan, 1982; Shibayama et al., 1994) and controlled by plasma inhibitors
(Weiss et al., 1986). Introduction of a surface or other polyanionic substances
could accelerate many thousand-fold the baseline turnover of Factor XII and
PPK to accelerate the cascade. The addition of the cofactor, HK, promotes
these reactions even further, but requires the surface to be present. The
surface appears to create a local milieu in the contiguous fluid phase (Griffin
and Cochrane, 1976; Griep et al., 1985) where the local concentrations of
reactants are greatly increased, which increases the rate of the reciprocal
interaction. In addition, surface-bound Factor XII undergoes a conformational
change that renders it more susceptible to cleavage (Griffin, 1978).
In plasma, the involvement of HK in the contact activation system was
discovered in a study on abnormal persons who had a prolonged partial
thromboplastin time (PTT) and no BK could be generated upon incubation of
their plasma with kaolin, but they were not deficient in Factor XII or PPK
(Colman et al., 1975; Wuepper et al., 1975; Donaldson et al., 1976). This
phenomenon was explained by the identification of HK as a non-enzymatic
cofactor in contact activation. It appeared to accelerate activation of both
Factor XII and PPK as well as Factor XI (Meier et al., 1977; Revak et al.,
1977; Wiggins et al., 1977). The discovery that PPK and Factor XII circulate
bound to HK, provided the mechanistic key to an explanation (Thompson et
al., 1977). One function of HK is to present the substrates of Factor Xlla in a
conformation that facilitates their activation. Thus, PPK that is bound to the
surface in the absence of HK is not subsequently activated by Factor Xlla
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(Silverberg et al., 1980). A synthetic peptide encompassing the HK binding
site for PPK can interfere with contact activation by competitively interfering
with the binding of PPK to the HK light chain (Tait and Fujikawa, 1987).
Similarly, a monoclonal antibody to this binding site inhibits coagulation and
kinin formation in plasma (Reddigari and Kaplan, 1989). Factor XI activation is
almost totally dependent upon the formation of a surface-binding complex with
HK.
1.6.6 The Complement System (Figure 1.6)
The classic complement pathway is activated by immune complexes, whereas
the alternative pathway is activated on the surfaces of damaged host tissues
and invading micro-organisms. The precursor protein, C1 (800 kDa), is
composed of a 460 kDa subunit (C1q) associated with two molecules each of
the 83 kDa polypeptides, C1s and C1r C1q(r,sh (Pixley and Colman, 1997).
Upon activation, C1 q dissociates and activates the protease form of C1 s.
Activated C1 s initiates a cascade resulting in formation of the membrane
attack complex (MAC), as well as release of C3a, C4a and C5a (Pixley and
Colman, 1997). These anaphylatoxins, acting on cell-surface receptors of
mast cells and basophils, release histamine and serotonin, thereby
contributing to microvascular leakage. C3a and C5a are also chemotactic for
monocytes and neutrophils (Pixley and Colman, 1997). Inactivation of C4b2a
occurs by dissociation of C2a from the complex and cleavage of bound C4b.
Factor I cuts C4b2a which occurs by dissociation of C2a from the complex


















Figure 1.6 Classical and alternative pathways of complement activation
classical and alternative complement activation pathways that are activated by
This figure shows the formation of a membrane attack complex (MAC) via the
immune complexes and damaged host tissue surfaces/micro-organisms
respectively. Subunits of C1, the precursor protein, initiate a cascade resulting
in the text (see 1.6.6).
in the formation of MAC. Detailed descriptions of these systems are described
~
.....t 'f












































































two sites releasing a large fragment C4c, and leaving the C4d attached to the
cell membrane. Inactivation of C3b occurs in a similar manner.
Direct activation of complement by bacteria and their products occurs, since
endotoxin and intact bacteria can activate complement via the alternate
pathway (Morrison and Kline, 1977). However, in vitro studies have
demonstrated a mechanism for activation of the classical pathway where
another cleavage product of Factor Xlla, Factor Xllf (30 kDa), can activate C1
through cleavage of C1 r (Ghebrehiwet et al., 1981; Ghebrehiwet et al., 1983).
Alternatively, kallikrein can cleave the C1 components, resulting in destruction
of C1. Kallikrein has been demonstrated to replace Factor D in the alternative
pathway, generating C3 convertase by cleaving Factor B (Di Scipio, 1982).
Kallikrein can generate C5a from C5 (Wiggins et al., 1981), suggesting that
the KKS may also activate complement.
1.7 PK in tissues
lmrnunocytochemlcal studies using monoclonal and polyclonal antibodies
showed that PPK occurs bound to domain 6 of the kininogen molecule located
on the external surface of the human neutrophil (Figueroa et al., 1992b).
Probing of the kinin moiety by a specific antibody demonstrated that kininogen
molecules bound to the neutrophil cell membrane were intact and contained
the kinin sequence, domain 4. Thus it appears that neutrophils may provide a
circulatlnq platform for the surface activation .of PPK and clotting factors
(Henderson et al., 1992). PK also appears to be involved in the conversion of
prorenin to renin (Sealey et al., 1978; Derkx et al., 1979).
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PPK synthesis in the liver was originally identified after reduced levels of PPK
were measured in the plasma of patients with liver cirrhoses (Colman and
Wong, 1979). Direct evidence of hepatic PPK synthesis came from
immunocytochemical studies using confocal microscopy which demonstrated
PPK in hepatocytes (Henderson et al., 1992). Previously, the inability to find
PK mRNA transcripts in any tissue other than the liver suggested that PK
does not normally function as a processing enzyme cleaving selected pairs of
basic amino acids in prohorrnones in vivo (Seidah et al., 1988). However, in
more recent studies PPK mRNA was demonstrated in RNA preparations from
whole tissues of kidney, adrenal gland and placenta by reverse transcription
polymerase chain reactions (RT-PCR) (Ciechanowicz et al., 1993; Hermann
et al., 1996). PPK mRNA is also expressed in the human brain, heart, lung,
trachea, endothelial cells, leukocytes, as well as a variety of fibroblast and
epithelial cell lines (Hermann et al., 1999). Expression of PPK mRNA in
fibroblasts, endothelial cells and leukocytes suggests that PPK mRNA
detected from whole tissue may originate from these ubiquitously occurring
cells. However, PPK mRNA expression in various epithelial cell lines
demonstrate that tissue-specific cells also transcribe the PPK gene. The
presence of PPK mRNA in non-hepatic cells indicates their capacity to
synthesise the protein. It appears therefore, that PPK may participate in local
actions within tissues as well as contributing to the PPK pool in blood plasma.
PK immunolocalisation has been demonstrated in human arteries suggesting
that kinins may play a role in maintaining and regulating vascular tone and
local blood flow (Cerf et al., 1999).
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Both PK and Factor Xlla can activate granulocytes (Wachtfogel et al., 1983;
Wachtfogel et al., 1986) and the complement system (Ghebrehiwet et al.,
1981; Ghebrehiwet et al., 1983; Di Scipio, 1982). Factor Xlla activates Factor
XI and thus triggers the intrinsic blood coagulation cascade. PK is an effective
activator of the precursor for urokinase-type plasminogen activator and
therefore provides a connection to the fibrinolysis system (Ichinose et al.,
1986; Hauert et al., 1989).
1.8 Hypothesis and aims of this study
Only a few studies, and that only recently, have reported on the cellular
expression of plasma kallikrein (PK) in mammalian tissues. Therefore, the aim
of this study is to identify, isolate and immunolocalise PK and to examine its
possible role in human tissues viz. the liver, pancreas, kidney, lung, salivary
gland, oesophagus, stomach, blood vessels (aorta, renal, coronary, basilar
and carotid arteries, inferior vena cava, renal vein) as well as the spinal cord
and various brain tissue (hypothalamus, frontal lobe, occipital lobe, pre-central
and post-central gyri, thalamus, pituitary gland, medulla, pons, hippocampus,
midbrain, choroid plexus and cerebellum). With the availability of specific
antibodies to PK, the capability to demonstrate PK in different human tissues
became possible. Also, evidence was needed to demonstrate whether extra-




2.1.1 Ethical approval and Patient/Guardian Consent
Ethical permission for this study was obtained from the Ethics Committee of the
Nelson R. Mandela School of Medicine, University of Natal. Permission for the
collection of post-mortem tissue samples was obtained from Professor M.A. Dada,
Head - Department of Forensic Medicine, University of Natal. Autopsy samples for
liver, pancreas, kidney, lung, submandibular salivary gland, oesophagus, stomach;
blood vessels (aorta, renal, coronary, basilar and common carotid arteries, inferior
vena cava, renal vein), upper cervical portion of the spinal cord and brain tissue
[frontal lobe, occipital lobe, pre-central and post-central gyri, hypothalamus,
thalamus, midbrain, pons, medulla, hippocampus, pituitary gland (both anterior
and posterior), choroid plexus and cerebellum] were collected at post-mortem,
performed within 24h of death, with the co-operation of the attending forensic
surgeon. Tissue samples of the liver, kidney, lung and salivary gland were
collected from all 10 patients. Pancreas and oesophagus samples were collected
from 9 patients, and only 4 sections of the stomach were collected due to autolysis
at post-mortem. Aorta samples were collected from 10 patients, whereas 9 sets of
each of the other blood vessels were collected. For the different brain regions,
sections were collected from 7 patients. All the tissue collected was placed in
physiological saline (0.9 % NaCl, pH 7; Sabax, SA) kept at 4°C. The samples were
then separated into 3 pieces: one placed in a cryotube and stored at -70°C,
another in physiological saline for homogenising, and the third fixed in 5% formal
saline (35% formaldehyde/physiological saline; Saarchem, SA) overnight for
paraffin-wax embedding. Consent was obtained from the families of the deceased
(See Annexure: Table 2.1.1).
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2.2 Sample Processing and Extract Preparation
2.2.1 Preparation of tissue extracts
The tissue stored in physiological saline was homogenised on ice in 1.5 ml
physiological saline with a hand held homogeniser (10 ml Down's) for 10 strokes.
To remove cellular debris and high molecular weight components, the
homogenates were centrifuged at 9923 xg (Heraeus Biofuge 13R, Heraeus
Sepatech, Germany) at 4°C for 10 min. The pellets containing cells and debris
were discarded, and the supernatant was stored for measurement of PK
concentration by ELlSA.
2.2.2 Tissue processing: fixation and wax embedding for light microscopy
Formal saline fixed tissue samples were orientated and set in plastic tissue
cassettes. The tissue samples were then processed by routine tissue fixation and
embedding techniques. Briefly, the tissue samples were dehydrated using
absolute ethanol (Saarchem, SA) and xylene (Saarchem), and then embedded in
paraffin-wax under sterile conditions, in an automatic tissue processor (Shandon,
UK). The automated fixation, dehydration, clearing, infiltration and embedding
were carried out by the Department of Histopathology, University of Natal. (For
detailed methodology see Raidoo, 1999).
2.2.3 Haematoxylin and Eosin (H&E) staining of wax-embedded tissue
Ultra-thin (3 urn) sections of the wax-embedded tissue were cut on a rotary
microtome (Jung RM2035, Leica, Germany) and floated onto glass slides (Lasec,
SA). The slides were allowed to air-dry and then stained with Mayer's
haematoxylin (Sigma, St. Louis) and eosin (Sigma) (H&E) to confirm the absence
of disease in the tissue samples and to ensure that tissue processing was optimal.
The following staining method was performed at room temperature (RT). The
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tissue was dewaxed in xylene (Saarchem, SA) twice for 5 min, then rehydrated
through a series of increasingly dilute ethanol (Saarchem) in distilled water (dH20 )
(100%, 90%, 70% v/v) for 1 min each, and finally into dH20 for 5 min. The slides
were then immersed in Mayer's haematoxylin for 5 min at RT, washed under
running tap water for 5 min to intensify the stain, immersed in eosin for 6 min, and
then rinsed in 95% ethanol for 30 seconds. The stained tissue slides were then
dehydrated in absolute ethanol twice for 1 min each, and finally into xylene. These
were then mounted with glass coverslips using a permanent mountant, Entellen
(Merck, Germany) (For detailed methodology see Raidoo, 1999).
2.3 Sample storage
2.3.1 Extracts for PK ELlSA
A volume of 40 JlI 40 mM Tris-HCI, pH 8 (PK cocktail) (Saarchem, SA) was added
to 1ml aliquots of each tissue extract to prevent PK degradation, and then stored
at -20°C for the subsequent determination of total PK by ELlSA.
2.3.2 Wax-embedded tissue
The wax-embedded tissue samples were stored at RT for future microscopic and
immunohistochemical analysis.
2.4 Anti-PK antibodies
Polyclonal anti-PK antibodies, raised in rabbit, were directed against PK (hPK
1060L, Enzyme Research Laboratories, USA). The lyophilised PK protein was
reconstituted in sterile physiological saline at a concentration of 1.654 mg/ml,
frozen in 50 JlI aliquots and maintained at -20° C.
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2.4.1 Generation of Rabbit anti-human PK antibody
Two healthy free-range adult rabbits were used to raise polyclonal antibodies to
PK. The animals were obtained from, and housed at the Biomedical Resource
Centre, University of Durban-Westville, Durban (ethical permission was obtained
from the University of Durban-Westville Ethics Committee) where all procedures
were performed under ketamine (100 mg/ml) anaesthesia at a dose of 2-3 mg/kg
body weight by intra-muscular injection (IMI). A volume of 2 ml blood was removed
from an ear vein of each rabbit prior to inoculation to test the non-immune serum
for cross-reactivity. For the initial inoculation, 150 ~g antigen was mixed with 150
~I Freunds complete adjuvent (Sigma, St. Louis). The rabbits were initially
immunised with 75 ~I conjugated antigen by IMI into each hind limb. For the first
booster injection, administered three weeks later, 100 ~g of antigen was mixed
with 100 ~I Freunds incomplete adjuvent (Sigma), and 50 ~I was injected into each
hind limb. For the remainder of the booster programme 50 ~g of PK, dissolved in
50 ~I 0.01 M phosphate buffered saline (PBS), pH 7.4 (Sigma), was conjugated to
100 ~I Freunds incomplete adjuvent, and 100 ~I conjugated antigen injected into a
hind limb of each animal. Subsequent similar booster injections were rotated
between limbs and administered at four-week intervals over a 4-month period.
Two days before each booster injection, and weekly after the final booster, 2 ml of
blood, removed from an ear vein, was used to determine cross-reactivity,
specificity and sero-conversion. The antibody titre was determined by a standard
single site ELlSA using PK. When the antibody titre increased from 1:100 and
finally plateaued at an optimum of 1:7000 after the final booster injection, the
animal was exsanguinated by cardiac puncture. The whole blood removed at each
bleed was allowed to clot at RT, centrifuged at 88 xg (Heraeus Megafuge 1.0R,
Heraeus Sepatech, Germany) for 20 min at RT, and the serum collected was
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stored at -20°C.
2.4.2 Isolation and purification of Immunoglobulin G (lgG) from rabbit serum
A Protein G Sepharose" 4 Fast Flow Column (Pharmacia Biotech, Sweden) was
used to separate IgG from serum. The column was stored in 20% ethanol (v/v).
Firstly, the ethanol was decanted and discarded. Then the sepharose column (5.5
ml in volume) was equilibrated with 3 bed volumes (15-20 ml) of 0.1M Tris-HCI, pH
8 (Sigma, St. Louis). 1 ml of rabbit anti-human PK anti-serum (from section 2.4.1)
was added to the column. The column was connected to a fractionator pump
(Gilson Pump, Abimed, Germany) at a flow rate of 1 ml/min, and the flow-through
was collected. A volume of 3 ml 0.1M Tris-HCI, pH 8 was added when the column
was almost dry and also collected. The column was stopped and 60 ml 0.1M Tris-
HCI, pH 8 was added without the use of the pump, and collected. This was
repeated using 60 ml 0.01 M Tris-HCI, pH 8. The addition of 0.1M and 0.01M Tris-
HCI, pH 8 was to facilitate the complete washing of all serum components out of
the gel, except for the IgG. To elute the IgG, 40 ml 0.1M glycine, pH 3 (Sigma)
was added to the column, which was connected to the pump (1 ml/min) and the
fractionator (2112 Redirac Fraction Collector, LKB, Sweden), and eluted into 44
ependorfs in 1 ml fractions. The pH of the eluted IgG fractions were checked with
litmus paper to determine at which fractions a pH of 8 was achieved, which is
optimal for the elution of IgG fractions from the column. The absorbances of the
eluted IgG fractions were read at OD280 using a Uvikon spectrophotometer 920
(Kontron, Italy) with 0.1 M glycine, pH 3 as a blank. OD280 =1.33 was taken as 1
mg/mllgG concentration. IgG fractions with the highest absorbances were pooled.
Sodium azide (0.02% w/v; Sigma) was added to the IgG pools, which were then
stored at -20°C. The column was then washed with 3 bed volumes of 0.1M
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glycine, pH 3 followed by washing with 0.01 M Tris-HCI, pH 8 and finally stored in
20% ethanol at 4° C (See Annexure: Table 2.4.2).
2.4.3 Quality control
The purity, immunospecificity and sensitivity of the antibodies were verified by
Western immunoblotting, a single site ELlSA using PK, positive control tissue and
pre-adsorption with PK in immunocytochemical studies.
2.4.3.1 Titre determination
The stepwise determination of the anti-PK antibody titre in rabbit serum by a
standard single site ELlSA using PK was as follows-
An aliquot of PK (hPK 1060L, Enzyme Research Laboratories, USA) (1.654 mg/ml
in sterile physiological saline stored at -20° C; Sabax, SA) was thawed at 4°C and
diluted to 5 IJg/ml in coating buffer (0.015M Na2C03, 0.035M NaHC03, pH 9.6;
Sigma, St. Louis). An ELlSA microtitre plate (Coming, USA) was coated with 100
IJI/well overnight at 4°C. The plate was washed 3X3 min each with 0.01 M PBS, pH
7.4 (Sigma)/0.05% Tween 20 (Saarchem, SA) (PBSlTween) at RT. All wells were
then blocked twice with 200 IJI milk blocker [10% fat-free bovine milk (Elite,
SA)/5% bovine serum albumin (BSA); Boehringer-Mannheim, Germany)] for 30
min each at RT, with a PBSlTween wash step in-between for 3X3 min. Serial
dilutions of the anti-serum (1 :200; 1:400; 1:800; 1:1600 and 1:3200) were made up
in 0.01 M PBS/1 % BSA (v/v) (PBS/BSA). Each dilution (100 IJI) was added in
triplicate to the plate and incubated for 1h at 37°C in a shaking water bath
(Tecator, UK). Blank wells were filled with 100 IJI PBS/BSA. The plate was then
washed 3X3 min each with PBSlTween at RT. Next, each well was loaded with
100 IJI of alkaline phosphatase conjugated anti-rabbit IgG (Sigma), diluted 1:250 in
0.01 M PBS/1 % BSA (v/v), and the plate incubated for 1h at 37°C in a shaking
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water bath. The plate was then washed 3X3 min each with PBSlTween at RT.
Finally, to facilitate chromogenic colour development, the plate was loaded 100
~l/well with 1 mg/ml phosphatase substrate, disodium paranitrophenyl phosphate
substrate (pNPP, Sigma, 1 tablet in 5 ml of MgCb/diethanolamine, pH 9.6,
substrate buffer, Sigma) and absorbances read at 405 nm on a Biorad Microplate
Reader 3550 (Biorad, UK) utilising Biorad Microplate Manager software, until
readings peaked at 1.0-1.5 absorbance units (For detailed methodology see
Raidoo, 1999).
2.4.3.2 Western blot analysis for rabbit anti-human PK IgG
2.4.3.2.1 Checkerboard Test
A serial dilution (200 ng/ml to 12.5 ng/ml) of PK antigen (hPK 1060L, Enzyme
Research Laboratories, USA) in PBS, pH 7.4 (Sigma) was done. Nitrocellulose
paper (20 urn pore size, Amersham, England) was cut into 8 mm wide strips
between cellophane wrapping and handled with forceps. Diluted PK antigen (1 /-11)
was then spotted 1 cm apart on the nitrocellulose paper. The protein was allowed
to air-dry for 1h between 3 urn Whatman paper (Whatman, England) and covered
with a plastic container to protect it from dust. Non-specific binding sites were then
blocked 2x10 min in 3 ml 10% blocking reagent (10% casein protein in maleic acid
buffer; Boehringer-Mannheim) in a Biorad transfer plate and placed on a shaker
(Adams Nutator 1106, USA ). Strips were then incubated in 3 ml of rabbit anti-
human PK antibody diluted 1:4000; 1:8000; 1:16000 at 4°C overnight on a shaker.
The nitrocellulose strips were then washed in 0.01M PBS, pH 7.4 (3X10 min/RT),
blocked with 10% blocking reagent for 30 min/RT, and incubated with anti-rabbit
IgG alkaline phosphatase conjugate (Sigma) diluted 1:5000 with 10% blocking
reagent for 1h at RT. The strips were then washed in detection buffer (0.1 M Tris-
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HCI, 0.05M MgClz, 0.1 M NaCl, pH 9.5; Boehringer-Mannheim) (3X10 min/RT). A
0.375 mg/ml NBT (nitro blue tetrazolium chloride)/0.188 mg/ml BCIP (5-bromo-4-
chloro-3-indoyl-phosphate) chromogen solution (Boehringer-Mannheim) was used
to develop the membrane for a few minutes in the dark at RT. When sufficient
colour development showed visible immunoprobed protein bands, the reaction
was terminated with 0.05M EOTA (ethylenediamine-tetraacetic acid, pH 8; Sigma)
for 5-10 min and then quenched with dHzO for 30 min. The membrane strips were
then scanned on a Scan Jet 11 C flat bed scanner (Hewlett-Packard, USA).
2.4.3.2.2 Western Blotting
Rabbit anti-human PK IgG (from section 2.4.2) was characterised by sodium-
dodecyl-sulphate polyacrylamide gel electrophoresis (SOS-PAGE) and Western-
blot transfer for specificity and purity as follows:
Electrophoresis: PK protein (hPK 1060L, Enzyme Research Laboratories, USA)
was run on a 15% SOS polyacrylamide gel. The 15% resolving gel and 5%
stacking gel were prepared according to the method of Sambrook (1989) (See
Annexure: Buffers and Reagents). 10 Jlg of PK protein was added to 7 JlI of
sample loading buffer (10% SOS w/v, 1% bromophenol blue w/v, 5% ~_
mercaptoethanol w/v, 1% glycerol w/v, 0.5M Tris-HCI, pH 6.8), heated on a
heating mantle (Thermolyne Dri-Bath, BarnsteadlThermolyne, USA) at 42°C for
1h, and then immediately plunged into ice. Low range molecular weight markers
(lysozyme 14.4 kOa, trypsin inhibitor 21.5 kOa, carbonic anhydrase 31 kOa,
ovalbumin 45 kOa, serum albumin 66.2 kOa, phosphorylase B97.4 kOa; Biorad,
UK) were also added to sample loading buffer (1:19) and heated. 10 JlI of
denatured protein and denatured molecular weight markers was loaded onto the
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SDS gel and electrophoresed at 160 mV for 1h using a discontinuous buffer
system (O.4M glycine, 0.02M '~'bS': 0.12M irf~:HCI, pH 8.3) on a Biorad Mini-
Protean" Electrophoresis Cell (Biorad, USA) using a Biorad Powerpac 3000 power
source. Controls for the electrophoretic run were 1 mg/ml human albumin (Sigma,
St. Louis) and rTK (generated in E. coli transfected with human TK cDNA, donated
by Dr. Michael Kemme, Institute for Biochemistry, Technical University of
Darmstadt, Darmstadt, Germany; similar concentration and denaturing conditions
as forPK). On completion of the run (determined when the dye front had reached
within 1 cm of the baseof the gel), the gel was removed from its apparatus.
Western blotting: The gel was ' equilibrated in transfer buffer (10% methanol,
0.025M Tris-HCI, 0.192M glycine, pH 8.3) for 15 min, as was filter blotting paper
(Whatman, cut to the same size as the gel) and 0.4'~m Biorad nitrocellulose
membrane. The 'gel sandwich' was assembled according to the Biorad Mini Trans-
Blot® Electrophoretic Transfer Cell instruction manual (Biorad), ' and protein
transfer was performed for 2h at" 90 mA.
Immunoblotting: Upon completion of the protein transfer, the membrane was cut in
two. .One part of the membrane was stained with India ink [50 ~I ink (Pelikan
Drawing ink A, Pelikan, Germany) in 50 ml of 0.3% Tween 20 (Saarchem,
SA)/O.01 M PBS, pH 7.4 (Sigma)], the other was immunoblotted. For India ink
staining: The blot was washed in 0.4% Tween 20/0.01 M PBS, pH 7.4, with two
changes of 25 rnl at5 min each (200 /-ll Tween 20 in 50 ml PBS). The blot was
placed in inksolution for 15 min (up to 18h) at RT-Ionger incubations increased
sensitivity. The blot was then destained by multiple washes with PBS, dried on
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Whatman paper, and then sealed in plastic for storage.
After transfer was completed, the membrane was blocked in 10% blocking reagent
[10% casein protein in maleic acid buffer; Boehringer-Mannheim, Germany] for 30
min at RT on a shaker. The membrane was then washed in PBS (3X10 min/RT)
on a shaker (AdamsNutator 1106, USA). Next, the membrane was incubated with
rabbit anti-human PK IgG (1 :4000 in 10% blocking reagent) overnight at 4°C on a
shaker. The membrane was then washed in PBS (3X10 min/RT), blocked with
10% blocking reagent for 30 min/RT, and incubated with anti-rabbit IgG alkaline
phosphatase conjugate (Sigma) diluted 1:5000 with 10% blocking reagent for 1h at
RT. The membrane was then washed in detection buffer (0.1 M Tris-HCI, 0.05M
MgCb, 0.1M NaCI, pH 9.5; Boehringer-Mannheim) (3X10 min/RT). A 0.375 mg/ml
NBT (nitro blue tetrazolium chloride)/0.188 mg/ml BCIP (5-bromo-4-chloro-3-
indoyl-phosphate) chromogen solution (Boehringer-Mannheim) was used to
develop the membrane for a few minutes in the dark at RT. When sufficient colour
development showed visible immunoprobed protein bands, the reaction was
terminated with 0.05M EDTA (ethylenediamine-tetra-acetic acid, pH 8; Sigma) for
5-10 min and then quenched with dH20 for 30 min. The membranes were then
scanned on a Scan Jet 11 C flat bed scanner (Hewlett-Packard, USA).
2.5 Immunocytochemistry (ICC)
2.5.1 Positive tlssueand method controls ICC
Initially, normal human liver was used as positive control tissue to demonstrate
localisation, upon previous evidence of PK abundance in such tissue (Bhoola et
al., 1992). Samples of fresh control liver were collected at post-mortem, fixed in
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5% formal saline and embedded in paraffin-wax (refer to section 2.2.2). During
each immunolabeling experiment, this tissue demonstrating the presence of PK in
the hepatocytes, served as a method control. Later, the pancreas was the
preferred positive control tissue, since more specific immunolabeling for PK was
demonstrated in cells of the islets of Langerhans.
2.5.2 Negative method controls for ICC
The absence of positive specific immunolabeling following preabsorption of the
primary antibody with an excess of PK demonstrated the specificity of the antibody
utilised. The rabbit anti-human PK antibody was diluted 1:500 with 0.01 M PBS, pH
7.4 and added to a 2 mg/ml stock solution of PK to yield a final concentration of 1
mg/ml antigen (PK). This antibody-antigen conjugate was incubated overnight at
4°C to allow maximum formation of antigen-antibody complexes. Following
centrifugation (427 xg at 4°C; Heraeus Biofuge 1.3 R, Heraeus Sepatech,
Germany) the supernatant replaced the primary antibody in the ICC experiments.
Normal pancreas was used as a method control (both positive and negative) for
each initial labeling experiment to detect PK immunolocalisation in other tissues.
Those tissue samples, from this initial labeling experiment, that showed a positive
signal were then repeated with a respective negative control where incubation with
the primary antibody was omitted and replaced with either PBS, non-immune
serum or primary antibody that had been preabsorbed with an excess of antigen.
Negative controls that showed false positive results were subjected to biotin
blocking experiments to eliminate endogenous biotin labeling.
2.5.3 Immunolocalisation of PK by immunoprecipitation
Sections of the wax-embedded tissue (3 urn) were adhered onto adhesive coated
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(poly-L-Iysine; Sigma, St. Louis) slides and used for the detection of
immunoreactive PK by standard histochemistry techniques, using polyclonal rabbit
anti-human PK IgG as the primary antibody, and conjugated antibodies containing
the peroxidase-antiperoxidase (PAP) immunoenzyme complex and
diaminobenzidine (DAB) as the chromogen visualised by light microscopy. Slides
containing wax-embedded tissue sections were placed on a hot plate (Nickel Electro,
Clifton, England) at 60De. The tissue was then dewaxed in xylene (Saarchem, SA)
for 2x10 min/RT. The tissue was rehydrated: 2x5 min/RT in 100% EtOH (Saarchem);
followed by 1x20 min/RT in 100% methanol (MeOH) (Saarchem); 2x4 min/RT in 90%
EtOH; 2x3 min/RT in 70% EtOH; and 1x5 min/RT in dH20. The tissue was then
boiled (80DC) in 0.01M sodium citrate (Na3C6Hs07.2H20, pH 6.0; Saarchem) for
antigen retrieval (Shi et al., 1991) at 3 min high and then at 5 min low in a microwave
oven (Sharp R-4A52, Japan). The tissue was allowed to cool at RT for 20 min, then
placed in dH20 for 5 min. A Dako PAP marker (Dako, Denmark) was used to encircle
the tissue which was then washed in PBS (Sigma)/1 % BSA (Boehringer-Mannheim,
Germany). The tissue was incubated in 20% hydrogen peroxide [(H202 (v/v);
Saarchem/80% MeOH (v/v)] for 4X10 min/RT under humidified conditions to quench
endogenous peroxidase activity, and then washed in PBS. It was further blocked for
20 min in 10% blocking reagent (10% casein protein in maleic acid buffer,
Boehringer-Mannheim). Endogenous biotin present in the liver, kidney and salivary
gland samples was blocked with extravidin alkaline phosphatase conjugate
(Sigma) diluted 1:20 in blocking reagent for 15 minutes under humidified
conditions. The tissue was incubated with rabbit anti-human PK IgG (from section
2.4.2) [primary antibody; diluted in 10% blocking solution- 1:500 for tissues (liver,
pancreas, kidney, lung, salivary gland, oesophagus and stomach), 1:800 for blood
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vessels, and 1:250 for brain sections were optimal] overnight at 4°C under humidified
conditions. The tissue was washed in PBS. The tissue was incubated with Biotin link
(Dako, Denmark) for 20 min/RT under humidified conditions, then washed in PBS.
The tissue was incubated with streptavidin (undiluted, secondary antibody; Dako) for
20 min/RT, then washed in PBS. The tissue was incubated with liquid DAB (Dako)
for 1-5 min/RT in darkness, washed in PBS, and counterstained in Mayer's
haematoxylin (Sigma) for 5min/RT. The tissue was washed in tap water for 5 min,
then dehydrated through 70% EtOH into xylene, and mounted in Entellan (Merck,
Germany). The tissue was examined using a light microscope (leica, Germany) (For
detailed methodology see Raidoo, 1999).
2.6 PK ELlSA
96 well microtitre ELlSA plates (Coming, USA) were loaded 100 ~l/well with 0.6
~g/~1 PK (hPK 1060l, Enzyme Research laboratories, USA) in coating buffer
(0.015M Na2C03, 0.035M NaHC03, pH 9.6; Sigma, St. Louis) and incubated at
4°C overnight. PK standards were prepared in ependorf tubes as follows: 600 ~I of
2 ~g/ml PK was serially diluted in 0.01M PBS, pH 7.4/1 % BSA (Boehringer-
Mannheim, Germany) (PBS/BSA) to 0.008 ~g/ml. A volume of 640 ~I 1:320 dilution
of human plasma in PBS/BSA was serially diluted in a similar manner to 1:20 480.
Then, an equal volume of 1:400 (previously determined as the optimal dilution by
serial dilutions) rabbit anti-human PK IgG was added to each dilution of PK
standards and human plasma, resulting in a final concentration of 1:800 rabbit
anti-human PK IgG. For the tissue samples, 200 ~I of each tissue extract (refer to
section 2.2.1) was pre-incubated with 200 ~I of 1:400 rabbit anti-human PK IgG.
Oesophagus tissue extracts were diluted 1:7 in PBS/BSA for detection within the
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curve limits. All standards and samples were incubated for 18h at 4°C. The
following day the wells were then washed with 200 III 0.01 M PBS (Sigma)/0.5%
Tween 20 (Saarchem, SA) (PBSlTween) 3X3 min each at RT. The wells were
blocked for 30 min at RT with 200 III 5% fat-free milk (Elite, SA) in PBSlTween,
which constituted the milk blocker. Next, 100 III of each standard and tissue
sample (in triplicate) was added to the wells. Blank wells (in triplicate) were filled
with 100 III of milk blocker. The plate was then incubated at 37°C for 1h in a
shaking water bath (Tecator, UK). The wells were then washed with 200 III
PBSlTween 3X3 min each at RT. Next, the microtitre plates were incubated 100
Ill/well with 1:1000 anti-rabbit IgG biotin conjugate (Sigma) for 1h at 37°C in a
water bath. The wells were again washed with 200 III PBSlTween 3X3 min each at
RT, then incubated 100 Ill/well with 1:250 extravidin alkaline phosphatase (Sigma)
for 1h at 37°C in a water bath. Finally, following a PBSlTween wash, the wells
were all loaded with 100 III of a 1 mg/ml chromogenic disodium paranitrophenyl
phosphate substrate (pNPP, Sigma, 1 tablet in 5 ml of MgCb/diethanolamine, pH
9.6- substrate buffer) and the colour was allowed to develop until the highest
absorbances peaked at 1 to 1.5 absorbance units. Readings were taken at RT
with a Biorad Microplate Reader 3550 (Biorad, UK) using Biorad Microplate
Manager software. The mean blank absorbance was subtracted from the
standards, controls and samples, and a curve of absorbance versus log PK
concentration was plotted. The log concentrations of the samples were




Appendix of buffers, reagents and methods
Table 2.1.1. Informed consent for the collection of autopsy tissue
To the surgical patient
I am Mr. M.E. Gerf. I wish to localise and examine the role of plasma kallikrein in
human tissues. To accomplish the above objective I will need a small piece of
tissue that the surgeon will remove during surgical procedure. Please consent to
the above so that I may be able to accomplish this investigation. You may refuse
to participate without suffering any prejudice in consequence.
(Name of patient) (Date)
Isiguli esizohlinzwa
Ngingu Mnumzane M.E. Cerf, usisayensi. Ngifisa ukucubungula ngeplasm
kallikrein emzimbeni womuntu. Ukuze ngiphumelele kulokhu ngizodinga
isicutshana esincane esizosikwa ngudokodela ozokuhlinza. Ngicela kuwe imvume
yalokhu ngoba ngemvume yakho ngiyethemba ukuthi lolucwaningo luzoba




I am Mr. M.E. Cerf. I wish to localise and examine the role of plasma kallikrein in
human tissues. I will need small samples of normal tissue that will most easily be
obtained from post-mortem procedure. Please consent to the above so that I may
be able to accomplish this investigation.
(Name of guardian) (Date)
Ummeki wesiguli
Ngingu Mnumzane M.E. Cerf, usisayensi. Ngifisa ukucubungula ngeplasma
kallikrein emzimbeni womuntu. Ukuze ngiphumelele kulokho ngizodinga
izicutshana ezincane esidunjini somufi ngenkathi kulolwa imbangela yokushona
kukamufi.Ngicela kuwe imvume yalokhu ngoba ngemvume yakho ngiyethemba
ukuthi lolucwaningo luzoba yimpumelelo.
(Igama lommeli wesiguli) (Date)
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Table 2.4.2 Isolation and purification of IgG from rabbit antiserum
STEP SOLUTION TEMP
Equilibrate the Protein G Sepharose" 4 Fast Flow Column (Pharmacia
RT1 Biotech, Sweden) with 20 ml 0.1M Tris-HCI, pH 8 (Sigma, St. Louis).
2 Add 1 ml rabbit anti-human PK anti-serum to the column. RT
Connect the column to a fractionator pump (Gilson Pump, Abimed,
3 Germany) at a flow rate of 1 ml/min, and collect the flow-through. RT
4 Add 3 ml of 0.1M Tris-HCI, pH 8 as column runs dry, and collect it. RT
Stop the column and add 60 ml 0.1M Tris-HCI, pH 8 (without the use
5 of the pump) and collect it. RT
6 Repeat using 60 ml 0.01M Tris-HCI, pH 8. RT
Addition of 0.1M and 0.01M Tris-HCI, pH 8 washes out all the serum
components from the gel, except for the IgG.
Add 40 ml 0.1M glycine, pH 3 (Sigma) to the column, which is
7 reconnected to the pump (1 ml/min) and to the fractionator (2112 RTRedirac Fraction Collector, LKB, Sweden). Now elute into 44
ependorfs in 1 ml fractions.
8 Determine (with litmus) at which fractions pH 8 is achieved- optimal for RTelution of fractions from column.
9 Read absorbances of the eluted IgG fractions at 00280 on a Uvikon RTspectrophotometer 920 (Kontron, Italy).
10 Use 0.1M glycine, pH 3 as a blank. Take 00280 =1.33 as 1 mg/mllgG RTconcentration.
11 Pool IgG fractions with the highest absorbances. RT
12 Add sodium azide (0.02% v/w; Sigma) to the pooled IgG fractions and RTstore at -20°C.
13 Wash the column with 15 ml of 0.1M glycine, pH 3, then with 0.01M
RTTris-HCI, pH 8 and store in 20% EtOH at 4°C.
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Table 2.6 PK ELlSA
STEP SOLUTION TEMP TIME
1. Coat the ELlSA plate (Coming, USA) with 100 III of 0.6 Ilg/ml PK 4
uC 18h
in coating buffer (dissolve 1.59 9 Na2C03 and 2.93 9 NaHC03 in
1 litre dH20; Sigma, St. Louis).
2. Pre-incubate the standards [600 III of 2 Ilg/ml PK (hPK 1060L, 4:Uc 18h
Enzyme Research Laboratories, USA) serially diluted in 0.01 M
PBS/1% BSA (PBS/BSA) to 0.08 Ilg/ml; 640 III of 1:320 human
plasma serially diluted in PBS/BSA to 1:20 480] and tissue
samples (200 III of each) with an equal volume of 1:400 rabbit
anti-human PK IgG.
3. Wash the plate with 0.01M PBS/0.5%Tween 20 (PBSlTween). RT 3X3 min
4. Add 200 JlI of 10% fat-free bovine milk (Elite, SA) in PBSlTween RT 30 min
(milk blocker) to each well.
5. Wash the plate with PBSlTween. RT 3x3 min
6. Incubate the plate with 100 Jll/well milk blocker (blanks), 37uC 1h
standards and for each of the samples (all in triplicate).
7. Wash the plate with PBSlTween. RT 3x3 min
8. Incubate the plate with 100 Jll/wellwith 1:1000 anti-rabbit IgG 37uC 1h
biotin conjugate (Sigma).
9. Wash the plate with PBSlTween. RT 3x3 min
10. Incubate the plate with 100 ul/well with 1:250 extravidin alkaline 31uc 1h
phosphatase (Sigma).
11. Chromogen- 100 JlI of 1 mg/ml pNPP substrate was added to 37uC 0-60
each well [1 tablet in 5 ml of substrate buffer (5 mM MgC12/10% min
diethanolamine, pH 9.8; Sigma)] and allow colour to develop.
12. Calculation- subtract the absorbance of the blanks from the
absorbance of the standards, controls and samples. Plot
absorbance versus concentration of PK standards. Read PK
concentration of samples and controls from this graph.
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Buffers and Reagents
Reagents for sample collection, processing, dissection, embedding, storage
and histological staining
1. Sterile normal saline (physiological saline) (0.9% NaCI, pH 7; Sabax, SA).
2. 5% formal saline (35% formaldehyde/0.9% NaCI, 1:7 v/v; Saarchem, SA).
3. Absolute ethanol (99% ethanol, analytical grade; Saarchem).
4. Xylene (analytical grade; Saarchem).
5. Paraffin-wax(Paraplast plus).
6. Mayer's haematoxylin (Sigma).
7. Eosin (Sigma).
8. Poly-L-Iysine (Sigma)- dilute 1:10 in dH20 in plastic-ware and store at 4°C for
3 months.
9. PK cocktail 40 mM Tris-HCI, pH 8- dissolve 4.8 9 Trizma base (Sigma) in 800
ml dH20 , adjust pH to 8 with HCI and volume to 1 litre.
10. Giemsa Stain (Sigma).
11. Acetic acid (analytical grade; Saarchem).
Reagents for isolation of IgG from serum
1. Protein G Sepharose'' 4 Fast Flow Column (Pharmacia Biotech, Sweden).
2. Rabbit anti-human PK antiserum from section 2.4.1.
2. 20% ethanol (v/v) (Saarchem, SA).
3. 0.1 M Tris-HCI, pH 8- dissolve 12.11g Trizma base (Sigma, St. Louis) in 800
ml dH20 , adjust pH to 8 with HCI and volume to 1 litre.
4. 0.01 M Tris-HCI, pH 8- dissolve 1.211g Trizma base (Sigma) in 800 ml dH20 ,
adjust pH to 8 with HCI and volume to 1 litre.
5. 0.1 M glycine, pH 3- dissolve 7.507g glycine (Sigma) in 800 ml dH20 , adjust
pH to 8 with HCI and volume to 1 litre.
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Reagents for Western blot analysis for rabbit anti-human PK IgG
1. Rabbit anti-human PK IgG from section 2.4.2.
2. Human plasma kallikrein (hPK 1060L, Enzyme Research Laboratories,
USA)- 1.654 mg/ml in sterile physiological saline, stored at -20°C.
3. 0.01M PBS, pH 7.4 (w/v)- dissolve 1 PBS tablet (Sigma, St. Louis) in 200 ml
dH20 .
4. 22 IJm Nitrocellulose paper (Amersham, England).
5. 3 IJm Whatman paper (Whatman, England).
6. Blocking reagent- 10% casein protein in maleic acid buffer (Boehringer-
Mannheim, Germany).
7. Anti-rabbit IgG alkaline phosphatase conjugate (Sigma).
8. Detection buffer- 0.1 M Tris-HCI, 0.05M MgCb, 0.1 M NaCI, pH 9.5
(Boehringer-Mannheim).
9. Chromogen- 0.375 mg/ml NBT (nitro blue tetrazolium chloride)/0.188 mg/ml
BCIP (5-bromo-4-chloro-3-indoyl-phosphate) chromogen solution
(Boehringer-Mannheim).
10. 0.05M EDTA (ethylenediamine-tetra-acetic acid, pH 8; Sigma).
11. 30% acrylamide stock solution (wlv)- dissolve 30g acrylamide (Sigma) and
1.07 9 N,N'-bisacrylamide (BDH, UK) in 100 ml dH20.
12. 1.5 M Tris-HCI, pH 8.8 (w/v)- dissolve 181 ,65g Trizma base (Sigma) in 800
ml dH20, adjust pH to 8.8 with HCI and make up to 1 litre.
13. 10% SDS (sodium dodecyl sulphate, w/v; Amresco, USA)- dissolve 10g
SDS in 100 ml dH20.
14. TEMED (BDH).
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15. 10% ammonium persulphate (APS w/v)- dissolve 10g APS (BOH) in 100 ml
dH20.
16. 0.5 M Tris-HCI, pH 6.8 (w/v)- dissolve 60.55g Trizma base (Sigma) in 800
ml dH20, adjust pH to 6.8 with Hel and make up to 1 litre.
17. Loading buffer (10% SOS, 1% bromophenol blue, 5% ~-mercaptoethanol,
1% glycerol, 0.5 M Tris-HCI, pH 6.8; Sigma).
18. Prestained low range molecular weight markers-lysozyme 14.4 kOa, trypsin
inhibitor 21.5 kOa, carbonic anhydrase 31 kOa, ovalbumin 45 kOa, serum
albumin 66.2 kOa, phosphorylase B 97.4 kOa (Biorad, UK).
19. Running buffer (O.4M glycine, 0.02M SOS, 0.12M Tris-HCI, pH 8.3).
20. Transfer buffer (10% methanol, 0.025M Tris-HCI, 0.192M glycine, pH 8.3).
21. 0.4% Tween 20/PBS (200 JlI Tween 20 in 50 ml PBS).
22. India ink solution [50 JlI India ink (Pelikan Drawing ink A, Pelikan, Germany)
in 50 ml 0.3% Tween 20/PBS].
Composition of Running and Stacking gels
Reagents 10% Resolving gel 5% Stacking gel
30% Acrylamide stock 5ml 830 JlI
1.5 M Tris-HCI, pH 8.8 3.8rnl 630 JlI (0.5 M Tris-HCI, pH 6.8)
dH20 5.9 rnl 3.4 ml
10% SOS 150 JlI 50 JlI
TEMEO 6 JlI 5 JlI
10% APS 150 JlI 50 JlI
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Reagents for immunocytochemical localisation of PK by
immunoprecipitation
1. Poly-L-Iysine (Sigma, St. Louis)- dilute 1:10 in dH20 in plastic-ware and store
at 4°C for 3 months.
2. Xylene (Saarchem, SA).
3. EtOH (Saarchem).
4. 0.01 M Sodium-citrate, pH 6.0 (w/v)- dissolve 2.94g Tri-sodium citrate in 800
ml dH20, adjust to pH 6 with HCI and make up to 1 litre.
5. 20% H202/80% MeOH (v/v)- mix 200 j.ll H202 (Saarchem) with 800 ul MeOH
(Saarchem) just before use.
6. 0.01 M PBS, pH 7.4 (w/v)- dissolve 1 PBS tablet (Sigma) in 200 ml dH20.
7. 1% non-immune rabbit serum.
8. Rabbit anti-human PK IgG from section 2.4.2.
9. Anti-goat IgG Biotin link (LSAB K0690, Dako, Denmark).
10. Streptavidin-peroxidase (LSAB K0690, Dako).
11. Chromogen- liquid DAB (K3465, Dako).
12. Counterstain- Mayers haemotoxylin (Sigma).
13. Mountant- Entellen (Merck, Germany).
Reagents and immunochemicals for PK ELlSA
1. Coating buffer (0.015M Na2C03, 0.035M NaHC03, pH 9.6; Sigma, St.
Louis)- dissolve 1.59 9 Na2C03and 2.93 9 NaHC03 in 1 litre dH20.
2. Substrate buffer (5 mM MgC12/10% diethanolamine, pH 9.8) - dissolve
0.10163 9 MgCI2 in 80 ml dH20, add 10 ml diethanolamine (Sigma), adjust
pH to 9.8 with HCI and make up to 100 ml with dH20.
3. 0.01 M PBS, pH 7.4 - dissolve 1 PBS tablet (Sigma) in 200 ml dH20 .
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4. 5% protein blocker- dissolve 5g fat-free bovine milk powder (Elite, SA) in
100 ml PBS. Make fresh.
5. 0.01 M PBS/0.5%Tween- dilute 100 J.!I Tween 20 (Sigma) in 200 ml 0.01 M
PBS.
6. Rabbit anti-human PK IgG from section 2.4.2.
7. Anti-rabbit IgG alkaline phosphatase (Sigma).
8. Disodium paranitrophenyl phosphate substrate (pNPP, 5 mg tablets,





Following ethical approval for the study from the University of Natal Ethics
committee, permission for the collection of post-mortem tissue samples from
.the attending Forensic Surgeon and consent from the families of the
deceased, the tissue samples were collected at autopsy. The details of the 10
patients in whom autopsies were performed within 24 h from death are
summarised in Table 3.1. Briefly, there were 2 females and 8 males, whose
ages ranged from 10 to 65 years (mean age = 36 years). The causes of death
were chest injuries (n =2), gun shot injuries (n =2), stab wounds (n =2),
myocardial infarction (n =1), hanging (n =1), strangling (n =1) and drowning
(n =1) with no injury to the head. From each of the 10 individuals, 28 different
tissues were collected.
3.2 Validation of the anti-PK antibodies raised
The specificity of the rabbit anti-human PK IgG was verified by Western blot
analysis and the localisation of PK in hepatocytes of human liver samples
obtained at autopsy. The optimal concentration of antigen and dilution of
antibody for Western blot analysis, determined by a checkerboard test, was
50 ng/ml PK (hPK 1060l) and 1:4000 dilution for rabbit anti-human PK IgG
(Figure 3.1 A).
The Western blot analysis (Figure 3.1 B) showed that the IgG was specific for
PK, since there was no cross-reactivity between the rabbit anti-human PK IgG
and tissue kallikrein (lane 9), human albumin (lane 7), as well as the proteins
in the low molecular weight marker {carbonic anhydrase, ovalbumin, serum
albumin and phosphorylase B (lane 6)}.
70
Table 3.1 Demographics of patients from whom tissue samples were
obtained at autopsy
Time between
Age Race Sex Cause of Death autopsy and
death
38 Black Male
Blunt injuries to chest and
15 h
neck
44 Black Male Penetrating chest injury 12 h
45 Asian Male Myocardial Infarction 17 h




to chest and abdomen
46 Black Male
Multiple stab wounds to
6h
chest and abdomen
65 Asian Female Strangled 16 h
33 Black Male
Multiple stab wounds to
23 h
chest and abdomen




to chest and abdomen
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Figure 3.1 Characterisation of rabbit anti-human PK IgG
A) Checkerboard Test
Figure 3.1 Characterisation of rabbit anti-human PK IgG
A) Checkerboard test for rabbit anti-human PK IgG
PK concentrations (ng/ml)
200 100 50 25 12.5
gel, electro-transferred onto a nitrocellulose membrane, and then stained with India
I India Ink stain (lanes 1-5): Proteins were resolved on a 15% SOS polyacrylamide
determined by this checkerboard test, was 50 ng/ml PK and 1:4000 dilution for rabbit
concentration of the antigen and dilution of the antibody for Western blot analysis,
A double dilution series of PK (hPK 1060l) antigen was spotted onto strips of
anti-human PK IgG.
nitrocellulose membrane then incubated with various dilutions of rabbit anti-PK IgG.
conjugated secondary antibody and the chromogen NBT/BCIP. The optimal
The bound antigen-antibody complex was detected with an alkaline phosphatase
\



























Ink. The first lane contained pre-stained low molecular weight markers [carbonic
B) India ink stain and Western blot
anhydrase 31 kOa, ovalbumin 45 kOa, serum albumin 66.2 kOa, phosphorylase B
97.4 KOa (Biorad, UK)]. lane 2 contained 15 Ilg human albumin. lanes 3 and 4
I







6 7 8 9
contained 10 Ilg PK and lane 5 contained 10 Ilg rTK.
11 Western Blot analysis (lanes 6-9): Proteins from SOS gel were electro-transferred
onto a nitrocellulose membrane and immunoblotted with rabbit anti-human PK IgG
diluted 1:4000. The bound antigen-antibody complex was detected with an alkaline
phosphatase conjugated secondary antibody (1 :5000) and the chromogen
NBT/BCIP. We demonstrate no cross-reactivity between rabbit anti-human PK IgG
and the proteins in the low molecular weight markers {carbonic anhydrase,
ovalbumin, serum albumin and phosphorylase B (lane 6)}, human albumin (lane 7) as
well as tissue kallikrein (lane 9).
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3.3 Immunohistochemical localisation of PK in human tissues
3.3.1 Immunohistochemical localisation of PK in positive control tissue
With the exception of a few inflammatory cells in the liver sections,
histopathological examination revealed that all of the hepatic (Figure 3.2 A)
and pancreatic (Figure 3.2 B) tissues were free from disease. The
immunolabeling of PK observed in the liver was diffuse as most of the
hepatocytes demonstrated some degree of immunolabeling (Figure 3.2 C),
whereas in the pancreas immunoreactive PK was specific in cells of the islets
of Langerhans and some acini (Figure 3.2 D). Therefore, the pancreas was
used as a positive control for each immunolabeling experiment. Intense
immunolabeling for PK was evident in the few inflammatory cells observed in
samples of hepatic tissue.
3.3.2 Immunohistochemical localisation of PK in other tissue
Kidney: H&E staining showed normal histology although five sections of the
tissue samples showed the presence of scattered inflammatory cells
Immunoreactive PK was evident in cells of the distal convoluted tubules
(Figure 3.3 A). No distinct immunolabeling for PK was visualised in cells of the
proximal convoluted tubules, loops of Henle, collecting ducts or in the
glomeruli.
Lung: H&E staining revealed that this tissue was essentially normal with the
exception of scattered inflammatory cells as well as anthracotic deposits in
nine of the ten samples that were collected. The epithelial cells of the
bronchiole and alveoli showed immunolabeling for PK (Figure 3.3 C).







Figure 3.2 Immunolocalisation of PK in control tissue: liver and pancreas
Liver: Hepatocytes H, erythrocytes Er and the portal vein PV of the H&E stained
tissue were visualised (A). Diffuse immunolabeling for PK was demonstrated in
the hepatocytes H (C). No immunoreactive PK was present in the hepatocytes H
or in scattered inflammatory cells I in the negative control (E).
Pancreas: The H&E stained tissue (8) demonstrated the acini Ac and cells of
the islets of Langerhans IL, and also confirmed the absence of disease and
preservation of normal histological structure. Immunoreactive PK was localised in
. cells of the islets of Langerhans IL and in some acini Ac (D). No immunolabeling
for PK in the cells of the islets of Langerhans IL or acini Ac was evident in the
negative control (F) where the primary antibody was preabsorbed with an excess
of antigen.
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Figure 3.3 Immunolocalisation of PK in human tissue
Kidney: Immunoreactive PK was demonstrated in cells of the distal convoluted
tubules Del (A). In the negative control (8), the glomerulus G and distal
convoluted tubule Del showed no immunolabeling for PK.
Lung: Immunoreactive PK was present in epithelial cells Epi of the bronchioles
Br and alveoli AI (C).
Salivary gland: Some acini Ac within the lobules were immunolabeled for PK.
No immunoreactive PK was visualised in the striated ducts SO (0).
\
. Oesophagus: Squamous epithelial cells Sq and stratified squamous epithelial
cells SSq of the submucosa labeled positively for PK (E).
Stomach: Immunoreactive PK was evident in deep glandular cells GI within the
fundus (F).
No PK immunoreactivity was demonstrated in either the striated ducts or in
the septa (Figure 3.3 D).
Oesophagus: Intense PK immunolabeling was observed in the glandular duct
and stromal cells of the submucosa (Figure 3.3 E). Diffuse immunolabeling for
PK was also seen in some smooth muscle cells of the muscularis mucosa.
Stomach: The H&E stained sections revealed the presence of inflammatory
cells in three of the stomach sections. Immunoreactive PK was present in
chief and glandular cells within the fundus (Figure 3.3 F), some cells in the
muscularis mucosa, and in the vascularised lamina propria.
PK was intensely immunolabeled in the few inflammatory cells observed in
some of the above-mentioned tissues. In all of the above-mentioned tissues
as well as in the blood vessels and brain sections, discussed subsequently,
the distribution of immunoreactive cells was similar. Since this was a
qualitative study, no quantitative assessment such as image analysis was
done.
3.3.3 Immunohistochemical localisation of PK in blood vessels
Histopathological examination of all the blood vessels displayed normal
morphology, with the exception of atheromatous plaques observed in one
sample of the aorta (n =10); five of the nine coronary arteries, four carotid,
three basilar and two renal arteries. The various layers of the blood vessels,
viz. the tunica intima, the tunica media and tunica adventitia showed varying
degrees of immunostaining, with the tunica intima showinq the most intense
immunolabeling for PK and tunica adventitia the least. The endothelial cells in
the tunica intima and smooth muscle cells in the tunica media of all the
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arteries examined, demonstrated immunolabeling for PK. Intense labeling was
visualised in the endothelial cells of the aorta (Figure 3.4 A), renal (Figure 3.4
C) and coronary (Figure 3.4 D) arteries. The foam cells, macrophages and
inflammatory cells present in the atheromatous plaques also showed intense
labeling for PK (Figures 3.4 C and D). Of the two veins examined, viz. the
inferior vena cava (Figure 3.4 E) and the renal vein (Figure 3.4 F), only the
former showed immunolabeling for PK as visualised in the endothelial and
smooth muscle cells. In the basilar (Figure 3.5 A) and the carotid (Figure 3.5
B) arteries immunoreactive PK was also observed in the endothelial cells. In
all of the arteries examined, immunolabeling for PK observed in endothelial
cells was of greater intensity relative to labeling in smooth muscle cells.
3.3.4 Immunohistochemical localisation of PK in brain
H&E staining confirmed all the brain sections to be free of disease, injury and
the preservation of normal morphology (Figure 3.5 C). Immunolabeling for PK
was seen in small neurons of the supra-optic nucleus of the hypothalamus
(Figure 3.5 D), and in neurons within the grey matter (Figure 3.5 E). In the
hypothalamic sections, ependymal cells lining the third ventricle also labeled
positively. In non-pyramidal neurons scattered in all layers of the grey matter
of the four cerebral cortical regions examined, viz. the frontal lobe, occipital
lobe, pre-central and post-central gyri (Figures 3.6 A-D respectively),
immunolabeling for PK was observed. Immunoreactive neurons were also
seen in specific nuclei within the thalamus (Figure 3.6 E) and in thalamic
nerve fibres. The identity of the thalamic nuclei needs to be elucidated in
further studies. Immunoreactive PK was visualised in secretory cells of the




Figure 3.4 Immunolocalisation of PK in human blood vessels
Aorta: Positive labeling for PK was evident in the endothelial cells En of the tunica intima
TI and smooth muscle cells SM of the tunica media TM (A). No immunoreactive PK was
visualised in the smooth muscle cells SM of the negative control (8) following
preabsorption of the primary antibody with an excess of antigen.
Renal artery (X1000): The endothelial cells En, macrophages M and inflammatory cells I
showed immunolabeled PK (C).
Coronary artery (X1000): Intense PK immunoreactivity was visualised in the endothelial
cells En as well as in the foam cells FC and macrophages M in the atheromatous plaque
\
AP (D).
Inferior vena cava: Immunoreactive PK was visualised in both endothelial En and smooth
muscle cells SM (E).
Renal vein (X400): No immunoreactive PK was detected in either the endothelial or
smooth muscle cells (F).
I _
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Figure 3.5 Immunolocalisation of PK in cerebral blood vessels and the
hypothalamus
Basilar (A) and carotid (B) arteries: Immunoreactive PK was visualised in
endothelial cells En of both cerebral arteries.
Hypothalamus: The H&E stained section (C) demonstrated ependymal cells Ep
lining the third cerebral ventricle, neurons of the supraoptic nuclei SuN, and
verified the absence of disease and preservation of histology. PK
immunoreactivity was evident in neurons of the supraoptic nuclei SuN and in
x ependymal cells Ep (0) as well as in neurons N within the grey matter (E).
Immunolabeling for PK was absent in neurons N of the negative control (F)
where the primary antibody was preabsorbed with an excess of antigen.
'\-.
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Figure 3.6 Immunolocalisation of PK in regions of the brain
Frontal lobe (A), occipital lobe (8), pre-central (C) and post-central gyri (0):
Immunoreactive PK was visualised in cell bodies of the neurons N in the grey
matter in all of these regions.
Thalamus: In the cytoplasm of the cell bodies in some neurons N within the
thalamus, immunolabeling for PK was evident (E).
Pituitary gland: Immunoreactive PK was demonstrated in a few secretory cells
S in the anterior lobe (F).
visualised in the posterior pituitary gland. In the spinal cord, labeling for PK
was observed in some neurons throughout the grey matter as well as in
ependymal cells lining the central canal (Figure 3.7 A). Immunoreactive PK
was observed in certain neurons of the medulla (Figure 3.7 B), pons (Figure
3.7 C) and midbrain (Figure 3.7 D). Fibre tracts in the medulla, pons and
hippocampus (Figure 3.7 E) also demonstrated the presence of
immunoreactive PK. Generally, immunolabeling of PK was more intense in the
grey matter than in the white matter, the only exceptions being the medulla,
pons and hippocampus where the myelinated nerve fibre tracts of the white
matter showed more intense immunolabeling. No immunoreactive PK was
visualised in the capillaries, epithelial cells or stromal tissue of the choroid
plexus (Figure 3.7 F) or in neurons in the outer molecular layer, inner granular
layer or Purkinje cells of the cerebellum.
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Figure 3.7lmmunolocalisation of PK in the spinal cord and various brain
regions
Spinal cord: Immunoreactive PK was evident in the cell bodies of the neurons N in
the grey matter as well as in the ependymal cells Ep lining the central canal (A).
Medulla (B), pons (C) and hippocampus (0): The presence of immunolabeled PK
in the cell bodies of some neurons N as well as in the myelinated fibre tracts Ft of
the white matter was demonstrated.
Midbrain: Here immunoreactive PK was visualised in cell bodies of the neurons N
~ scattered throughout the midbrain (E). The nuclear localisation and identity of the
neurons remain to be verified .
Choroid plexus: No immunoreactive PK was visualised in the capillaries, epithelial
cells or stromal tissue (F).
..-
3.4 Measurement of PK by enzyme linked immunosorbent assay (ELlSA)
A standard curve measuring varying amounts of PKlPPK in a competitive
ELlSA was plotted (Figure 3.8). The detection limits of the curve were 0.008 -
2 ~g/ml for the PK standards. For each ELlSA experiment a sample of pooled
human plasma was used as controls. The plasma was extracted from whole
blood of a normal volunteer and stored in aliquots at -20°C. A serial dilution of
these plasma standards (1 :320 to 1:20 480 in PBS/BSA) was added in
triplicate to the wells as a positive method control for each ELlSA experiment,
and to determine the inter-assay (0.998) and intra-assay (0.967) coefficients
(Figure 3.9).
The highest amounts of immunoreactive PK were measured in pancreas
(12.94 ± 2.04 ~g/ml - diluted 1:7 in PBS/BSA in order to be detected within the
limits of the standard curve) and oesophagus (1.84 ± 1.45 ~g/ml) (Figure
3.10).
In the various blood vessels examined, the aorta (0.44 ± 0.14 ~g/ml), coronary
(0.21 ± 0.07 ~g/ml) and carotid (0.21 ± 0.08 ~g/ml) arteries had the highest
PK concentrations (Figure 3.10). In the brain sections, the pons (1.67 ± 1.46
uq/rnl), thalamus (0.67 ± 0.34 ~g/ml), pre-central gyrus (0.38 ± 0.24 ~g/ml),
frontal lobe (0.36 ± 0.16 ~g/ml) and pituitary gland (0.36 ± 0.13 ~g/ml) had the
highest PK concentrations relative to the other brain regions (Figure 3.10).
Tissues with the least amount of immunoreactive PK (less than 0.1 0 ~g/ml)
were the basilar artery and the spinal cord (Figure 3.10).
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Correlation Coefficient = 0.996
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Figure 3.9 Plasma Standard Curve
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Table 3.2 PK immunolocalisation in human tissue
Mean ELlSA PK
Tissue type PK Immunolocalisation concentration (f.lg/ml)
±SEM
Liver Hepatocytes 0.42 ± 0.08
Pancreas
,
- Islets of Langerhans I Acini 12.94 ± 2.04
Kidney Cells in distal convoluted tubules 0.46 ± 0.09
Lung Epithelial cells in bronchioles and alveoli 0.50 ± 0.19
Salivary gland Acini 0.39 ± 0.15
Oesophagus Squamous and stratified squamous epithelial cells 1.84 ± 1.45
Stomach , Glandular cells 0.27 ± 0.10
BLOOD VESSEL Endothelial cells Smooth muscle cells I,' 0
"
Aorta ) '+ + 0.44 ± 0.14
Renal artery + + 0.12 ± 0.06
Coronary artery + + 0.21 ± 0.07
Inferior vena cava + + 0.17 ± 0.05
Renal vein - - 0.16 ± 0.04
Basilar artery + + 0'.09 ± 0.07





Hypothalamus + + - 0.19 ± 0.07
Frontal lobe + - - 0.36 ± 0.16
Occipital lobe + - - 0.22 ± 0.07
Pre-central gyrus + - - 0.38 ± 0.24
Post-central gyrus + - - 0.10 ± 0.03
Thalamus + - - 0.67 ± 0.34
Pituitary gland* - - - 0.36 ± 0.13
Spinal cord + + - 0.09 ± 0.04
Medulla + - + 0.24 ± 0.1
Pons + - + 1.67 ± 1.46
Hippocampus + - + 0.18 ± 0.1
Midbrain + - - 0.28 ± 0.18
Choroid plexus - - - 0.30 ± 0.15,
Cerebellum - - - 0.25 ± 0.13
+ :: immunolabeling for PK - :: no immunolabeling for PK
*immunolabeling for PK was visualised in the secretory cells
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Table 3.2 Detection of PK in human tissues
This table demonstrates the specific localisation (by immunocytochemistry) of
plasma kallikrein as well as its concentration (given in Jlg/ml as determined by
ELlSA) in various human tissues, vasculature and brain regions. In the control
tissues, pancreas and liver, PK was present in the islets of Langerhans cells
and some acini in the pancreas as well as in hepatocytes. In kidney, the distal
tubules showed immunoreactive PK, whereas the epithelial cells in the
bronchioles and alveoli of the lung also labeled positively for PK. In
gastrointestinal tract tissues, acinar cells in the lobules of the salivary gland,
squamous and stratified squamous epithelial cells of the oesophagus, and
some glandular cells of the stomach demonstrated the presence of
immunoreactive PK.
The endothelial cells and smooth muscle cells of all the blood vessels
examined were immunolabeled with PK, except for the renal vein where no
immunoreactive PK was detected in either cell type.
In the spinal cord and brain, the cell bodies of some neurons in all of the
various brain regions examined were immunolabeled for PK, apart from the
choroid plexus and cerebellum. The presence of immunoreactive PK was also
evident in ependymal cells lining the third ventricle and central canal of the
hypothalamus and spinal cord respectively. Fibre tracts of the pons,
hippocampus and medulla as well as secretory cells of the pituitary gland also
demonstrated immunoreactive PK.
CHAPTER FOUR
4.1 Western blot analysis for rabbit anti-human PK antibody
Lane 8 for PK on the immunoblotted membrane (Figure 3.1 B) showed three
bands, and not a sharply defined distinct single band of 88 kDa. This is
probably due to the cleavage of the PPK molecule during the denaturing step
at 42°C for 1h. Hence, we observe a band of PPK at 88 kDa, and two others
representing the heavy and light chains of PK at 55 kDa and 33 kDa
respectively. The purpose of characterising the antibody is to demonstrate its
specific interaction with the antigen and no non-specific cross-reactivity with
other control proteins. Although three bands are observed in lane 8, this does
not compromise the specificity of the antibody since the membrane clearly
shows that the only interaction occurring with the rabbit anti-human PK IgG is
with the PK protein exclusively. Therefore we can conclude that our anti-
human PK IgG raised in rabbit is specific for the PK protein.
4.2 PK in control tissue (liver and pancreas)
PK has been immunolocalised in human hepatocytes (Henderson et al., 1992)
and is long believed to be synthesised in these cells (Mandle et al., 1976).
The liver is the main organ involved in PK clearance from circulation in vivo
(Borges and Kouyoumdjian, 1992). Ciechanowicz et al. (1993) have shown
the presence of PPK mRNA in human and rat liver using RT-PCR. The
findings of these studies would support the diffuseimmunolabeling for PK
visualised in hepatocytes and the PK concentration of 0.42 ± 0.08 !J.g/ml
measured by competitive ELlSA. It appears that PK, after synthesis in
hepatocytes, is released into the circulatory system upon demand. Although
the liver is regarded as the major source of circulating PK similar to other
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plasma proteins such as albumin, we speculate that PK may also be involved
in regulating some aspects of hepatic function such as the processing of
nutrients and detoxifying pathogens.
The pancreas is a complex gland characterised by the richly vascularised
mucous and serous acini (that contain secretory zymogenic granules),
connective tissue and ducts constituting the exocrine portion; and the islets of
Langerhans which are endocrine in nature (Junqueira et al., 1995). The latter
are clusters of epithelial cells (Craigmyle, 1986) which produce and secrete
the blood-glucose regulatory hormones insulin (p-cells), glucagon (a-cells)
and somatostatin (8-cells) directly into the blood via fenestrated capillaries
(Seeley et al., 1996). Although whole pancreas extracts demonstrated high
kallikrein activity decades ago (Kraut et al., 1930), and only recently human
pancreas extracts were shown to have a high copy number of PPK mRNA by
real time RT-PCR (personal communication: Mr Peter Neth), the exact cellular
localisation had not yet been described. We show, for the first time, distinctive,
specific immunolabeling for PK in cells of the islets of Langerhans and in
some acini. The ELlSA results showed that pancreatic extracts had the
highest PK concentration (12.94 ± 2.04 Ilg/ml) amongst all the tissues
examined. Frey et al. (1932) first reported the hypoglycaemic effect of
kallikrein where a decrease in circulating glucose was noted in diabetic
patients. Studies have shown that infused BK doubled muscle glucose uptake
in patients with postoperative stress syndrome (reviewed in Bhoola et al.,
1992). Since we have not established in which cell type of the islets of
Langerhans PK is expressed, an extension of this study using specific stains
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for these cells is required. However, we postulate that PK in these cells may
have a regulatory role in the processing and for secretion of insulin and
thereby control glucose uptake and utilisation in muscle cells, which may be of
clinical significance in conditions such as diabetes mellitus. B2 receptor
mRNA has been demonstrated in whole pancreas extracts by competitive
PCR using human cDNA (Hess et al., 1992). Hence, PK may release BK,
which could act at B2 receptor level to regulate pancreatic function. Therefore
an endogenous PKKS may be implicated, possibly in conjunction with other
physiological systems, to maintain pancreatic homeostasis. We propose that
PK may be involved in the processing of insulin precursors, and that by the
release of BK, may subsequently result in B2-mediated insulin release.
Lembeck and Griesbacher (1996) have postulated that kinins may have a
modulatory role in the production of pancreatic juice and in microcirculatory
regulation of the pancreas.
4.3 PK in kidney
The nephron, the functional and structural unit of the kidney (comprising of
glomeruli, proximal tubules, loops of Henle, distal tubules and collecting
ducts), is involved in water and electrolyte regulation. Studies employing real-
time RT-PCR showed that human whole kidney extracts had high copy
numbers of PPK mRNA (personal communication: Mr Peter Neth). We have
demonstrated the cellular localisation of PK in the distal convoluted tubules by
ICC. Also, a PK concentration of 0.46 ± 0.09 ~g/ml was determined by ELlSA
in whole kidney extracts. Other components of the KKS that have been
demonstrated in the kidney include TK and kinin receptors. The localisation of
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TK in distal tubules and the connecting duct cells is well established
(Schacter, 1980; Naicker et al., 1999). Subsequent studies show that 82
receptor mRNA had the highest expression in the kidney compared to various
other tissues (Hess et al., 1992). In normal human kidney, 82 receptor was
immunolocalised in the nephron using specific antibodies directed against the
82 receptor peptide and confocal microscopy (Naicker et al., 1999). In
addition, 81 receptors were immunolabeled in glomeruli, distal tubules and
collecting ducts of patients with renal diseases such as acute tubular necrosis,
nephritis and hypertensive nephrosclerosis, suggesting upregulationof these
receptors in renal parenchymal disease (Naicker et al., 1999). Wang et al.
(1996) localised 81 receptor mRNA in epithelial cells of the parietal layer of
8owman's capsule and in loops of Henle of normal kidney, as well as in
tumour cells of renal cell carcinoma patients by in situ hybridisation using a
digoxigenin-Iabeled probe. We postulate that PK, visualised in the distal
tubules elicits physiological effects via the release of 8K, which would be
mediated by 82 receptors found in the nephron. These effects may include a
role in influencing urine concentration and volume as Margolius (1996)
postulated, as well as in ion and water homeostasis. Intrarenal kinins
modulate renal excretory function predominantly by effects on renal
vasculature (Margolius et al., 1996). Components of the KKS demonstrated in
the kidney suggests that it acts in a paracrine fashion to regulate glomerular
function, renal haemodynamics as well as ion and water excretion (Margolius
et al., 1996;Sharma et al., 1996).
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4.4 PK in lung
Alveoli form the mass of lung parenchyma (Di Fiore, 1974), open into alveolar
ducts, and are the main sites of gaseous exchange between inspired air and
blood (Junqueira et al., 1995). Recently Hermann et al. (1999) reported the
expression of PPK mRNA in whole extracts of human lung using RT-PCR. We
immunolocalised PK in epithelial cells of the bronchioles and alveoli and
demonstrated PK in whole tissue extracts of the lung (0.5 ± 0.19 ~g/ml) by
ELlSA. Since the PPK gene is also transcribed in epithelial cell lines
originating from different organs (Hermann et al., 1999), the expression of
PPK mRNA may take place in tissue-specific epithelial cells throughout an
organism. This would provide a feasible explanation for the presence of
immunoreactive PK in the epithelial cells of the lung. In bronchoalveolar
lavage fluid of patients with asthma, kininogenase activity similar to TK was
detected by cleavage of a radiolabeled HK C251-HK) (Christiansen et al.,
1987). High levels of kinins have also been detected in bronchoalveolar
lavage fluid of patients with acute pneumonia and chronic bronchitis by
specific radioimmunoassay, as well as an increase in PPKlPK concentration
measured by sandwich ELlSA (Zhang et al., 1997). We propose that the
PPKlPK measured in these lavages was due to the presence of PK in the
epithelial cells of the bronchioles and alveoli as demonstrated in our study. TK
has been immunolocalised in serous cell granules of the seromucous glands
of human extrapulmonary and intrapulmonary bronchi (Poblete et al., 1993).
The presence of PK, TK and 82 mRNA (Hess et al., 1992) in the human lung
suggests that the KKS may be actively involved lung pathophysiology. During
asthmatic attacks, concentrations of free circulating kinins have been shown
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to increase from 0.1 ng/ml to 8 ng/ml which is significant since kinins are
highly active bronchoconstrictors (Werle, 1972) and potent inducers of edema
in human asthma (Christiansen et al., 1987). PK visualised in epithelial cells
could release 8K that may act on smooth muscle cells causing
bronchoconstriction thereby eliciting an asthmatic response. Werle (1972)
suggested that kinins may contribute to the development and aggravation of
emphysema. Immunofluorescence for 81 receptors in transbronchial tissue of
patients with sarcoidosis and interstitial lung disease has been visualised in
areas of fibrosis, in thickened interstitium, as well as in basement membranes
of capillaries and alveoli (Nadar et al., 1996). The presence of 81 receptors in
fibrosis is perpetuated by kinins, suggesting kinin involvement in the
pathogenesis of interstitial lung disease (Nadar et al., 1996). Immunolabeled
PK, as demonstrated in the epithelial cells of the alveoli, could generate 8K,
thereby potentiating lung inflammation via 81 receptor mediation.
Antagonists, like HOE-140 (icatibant) have shown success in down-regulating
the pathophysiological effects of kinins in clinical trials. In patients with allergic
rhinitis induced by house-dust mite, this 82 receptor antagonist, administered
by intranasal aerosol, significantly reduced nasal blockage induced by antigen
challenge (Austin et al., 1994). Other studies have shown that nebulized
icatibant results in a dose-dependent improvement in objective pulmonary
function tests in adult patients with chronic asthma, suggesting an anti-
inflammatory effect (Akbary et al., 1996).
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4.5 PK in gastro-intestinal tract tissue
4.5.1 Salivary gland
Salivary glands have mucous and serous acini, which secrete saliva
(containing mucous, enzymes, antibodies and inorganic ions) via secretory
ducts into the mouth (Di Fiore, 1974). Although immunolabeling for TK has
been demonstrated in the apical region of duct cells (Schacter, 1980; Naidoo
et a/., 1999b), PK has not yet been localised in the salivary gland. In this study
we have shown PK immunolocalisation in salivary gland acini. We have not
established whether these acini are serous or mucous in nature. A PK
concentration of 0.39 ± 0.15 Ilg/ml was measured by competitive ELlSA in
salivary gland extracts. Both TK (Bhoola et a/., 1992) and kinins (Margolius,
1996) are known to occur in saliva. We speculate that PK could release BK in
saliva, or alternatively, it may be involved in the processing of the proteolytic
enzymes secreted in saliva.
4.5.2 Oesophagus
The mucosa, submucosa, muscularis externa and adventitia constitute the
wall of the oesophagus; with the submucosa (broad connective tissue layer)
characterised by adipose cells, blood vessels and glands that secrete mucous
(Junqueira et a/., 1995). Application of a BK patch to the epicardia of the left
ventricle produced transient relaxation of the lower oesophageal sphincter in
dogs (Caldwell et a/., 1994). Other studies have shown that BK stimulation of
motor nerves associated with the muscularis mucosa results in concentration-
dependent contraction of the oesophageal muscularis mucosa in rabbits
(Percy et a/., 1997). Hence it appears that BK has a regulatory role in
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oesophageal function. Since smooth muscle cells transport food down the
oesophageal tract by peristalsis, the presence of immunoreactive PK in
squamous cells suggests that 8K may be released which then acts on the
smooth muscle cells resulting in peristaltic contractions. A PK concentration of
1.84 ± 1.45 Ilg/ml was measured by ELlSA in oesophageal extracts. More
recently TK (in giant tumour and mast cells of squamous cell carcinoma) as
well as both 81 and 82 receptors (in giant cells) were immunolocalised in
human oesophageal carcinoma, suggesting an influence of the KKS in
tumorigenesis of the oesophagus (Dlamini et al., 1999).
4.5.3 Stomach
The stomach (consisting of the cardia, fundus, body and the pylorus), is
characterised by the mucosa, submucosa, muscularis externa, serosa
(Junqueira et al., 1995), and gastric glands in the lamina propria which contain
the chief and parietal cells (Di Fiore, 1974). Recently TK was immunolocalised
in parietal cells of the pylorus, with elevated levels measured by ELlSA in
gastric lavage fluid of patients with gastritis (Naidoo et al., 1999a).
Immunohistochemical studies have demonstrated the presence of 82
receptors in parietal cells of normal stomach, and 81 receptors in neck glands
of regenerating stem cells in patients with gastritis (8hoola et al., 1997). The
presence of PK in glandular cells, which secrete digestive enzymes and
gastric acid, suggests that the PKKS may be important in processing digestive
enzymes. Furthermore, a PK concentration of 0.27 ± 0.10 Ilg/ml was
determined by ELlSA in stomach extracts. This relatively low PK
concentration (compared to the control tissues, kidney, lung and other gastro-
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intestinal tract tissues) may be due to PK degradation by autolysis in the
stomach. We speculate that the PKKS may be involved in maintaining gastric
homeostasis, and has an aggravating role in gastritis via the generation of BK
as postulated by Bhoola et al. (1997) and Naidoo et al. (1999).
4.6 PK in inflammation and disease
Neutrophils, isolated using cell fractionation techniques and then incubated
with immune complexes, granules and Iysosomes, released an enzyme
capable of liberating a kinin-like substance from kininogen (Bhoola et al.,
1992). HK has been identified in Iysates of washed neutrophils by competitive
ELlSA (Gustafson et al., 1989). Immunohistochemical studies demonstrating
TK in the human kidney, showed that neutrophils infiltrating a region of
infection within renal parenchyma had an intense granular pattern of
immunostaining (Bhoola et al., 1992). Blood smears from patients with chronic
myeloid leukemia have also shown intense immunostaining for TK in
neutrophil precursor cells, notably in myelocytes and metamyelocytes
(Figueroa and Bhoola, 1989).
In this study, intensely labeled PK was visualised in inflammatory cells of the
liver, lung and stomach. Inflammatory cells were expected in the liver since it
is involved in detoxification. Anthracotic deposits evident in some lung
sections would be responsible for the occurrence of scattered inflammatory
cells. Since gastric contents are acidic (due to the secretion of Hel) and
involved in chemical digestion, inflammatory cells would be present as part of
the homeostatic interface. It appears that the PKKS, through the release of
BK, contributes to the inflammatory response. Vasodilation (which increases
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blood flow to the area of pathology), nociception (which would be experienced
during inflammation), increased vascular permeability (which would allow the
easy transport of ions and water across the cell membrane ultimately resulting
in edema), and increased cell proliferation (for example macrophages which
occur during inflammation), are all kinin-produced effects which contribute to
the inflammatory response. Evidence that activation of circulating PK may
contribute to the aetiology of asthma, blood transfusion reactions, pancreatitis,
pulmonary edema and shock induced by haemorrhage, burns and endotoxins
was provided by Webster (1968).
4.7 PK in blood vessels
Arteries and veins, which are involved in blood transport, nutrient distribution
and some aspects of temperature regulation, have a common basic structure
comprising of the tunica intima, a single layer of flattened epithelial cells
(endothelium), an intermediate smooth muscular layer constituting the tunica
media, and the outer supporting tissue layer known as the tunica adventitia
(Young and Heath, 2000).
TK, as well as 81 and 82 receptors have been immunolocalised in endothelial
and smooth muscle cells of various human blood vessels using specific
antibodies for TK, 81 and 82 receptors respectively (Raidoo et al., 1997). In
this study we have shown immunolabeling for PK in the endothelial and
smooth muscle cells of the aorta; in endothelial cells of the renal, coronary,
basilar and carotid arteries; and in both the endothelial and smooth muscle
cells of the inferior vena cava. In addition, the highest PK concentrations
measured by ELlSA were 0.44 ± 0.14 Jlg/ml in the aorta, 0.21 ± 0.07 Jlg/ml in
98
the coronary artery and 0.21 ± 0.08 Ilg/ml in the carotid artery; with lower
levels detected in the renal (0.12 ± 0.06 Ilg/ml) and basilar (0.09 ± 0.07 Ilg/ml)
arteries. Immunolabeling for PK in medium to small muscular arteries, viz. the
coronary, carotid and basilar, suggests a functional role for kinins in the
maintenance and regulation of vascular tone, the loss of which may contribute
to the pathogenesis of hypertension. Kinins have been shown to promote
arterial dilation, constriction of veins, and capillary permeability thereby
enhancing the extravasation of plasma proteins and fluid. In severe
hypotension, these actions increase the severity of shock. Sharma et al.
(1996) postulated that the KKS is involved in cardiovascular protection and in
regulating blood pressure, therefore reduced formation of BK due to genetic
effects/environmental alterations, may enhance hypertension.
Local blood flow in tissues is regulated by changes in the diameter of
arterioles produced by relaxation and constriction of vascular smooth muscle.
BK released by the action of PK, in the endothelial and smooth muscle cells of
the various blood vessels examined, may play a role in controlling local blood
flow via its vasodilatory action. We speculate that PK localised in the
endothelial cells may release BK, which subsequently acts on smooth muscle
cells resulting in smooth muscle relaxation and increased blood flow.
4.8 PK in atheromatous disease
With advancing age, the accumulation of cholesterol and associated
atherosclerosis cause the arterial system to lose its elasticity thereby
increasing peripheral resistance and thus arterial blood pressure (Young and
Heath, 2000). An increase in immunoreactive TK has been demonstrated in
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endothelial cells and macrophages within atheromatous plaques of various
arteries (Raidoo et al., 1997). Furthermore, intense labeling for 81 and 82
receptors in endothelial cells, macrophages, inflammatory cells and
proliferating fibroblasts suggests that these receptors are upregulated within
atheromatous plaques (Raidoo et al., 1997). The intense immunolabeling for
PK that we observed in macrophages and foam cells of arteries afflicted with
atheromatous disease viz. the aorta, coronary, carotid, renal and basilar
arteries, suggests that its expression may be increased in atherosclerosis
resulting in the stimulation of 8K release to overcome the vasoconstrictor
effect of the plaque as Raidoo et al. (1997) hypothesised. This may possibly
be mediated by both the 81 and 82 receptors localised within the
atheromatous plaques.
4.9 PK in the brain
The brain is a large complex organ composed of neurons (the functional units
of the nervous system made up of cell bodies, dendrites and axons) as well as
supporting neuroglial cells (ependyma, oligodendrocytes, microglia and
astrocytes). Groups of cell bodies and dendrites in the cerebral cortex, brain
stem, cerebellum, central region of the spinal cord and basal ganglia form
grey matter, whereas bundles of myelinated axons constitute the white matter
forming fibre tracts for the conduction of nerve signals (Seeley et al., 1996).
Each region of the- brain has various specialised functions, for example the
hypothalamus has control centres including one for the regulation of body
temperature; the pituitary gland synthesises and secretes numerous
hormones; and other regions viz. the spinal cord, thalamus and hypothalamus
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work together in the modulation of pain as well as subserving other functions
(Seeley et al., 1996).
High copy numbers of PPK mRNA in total human brain extracts,
demonstrated by real time RT-PCR (personal communication: Mr Peter Neth)
identified a potential study to define where exactly in the brain PK is
regionalised. In this study, we immunolocalised PK in some neurons of the
spinal cord and in different brain regions viz. hypothalamus, cerebral cortex,
thalamus, brain stem and hippocampus. PK concentrations measured in brain
extracts by ELlSA were 1.67 ± 1.46 J,lg/ml in the pons, 0.67 ± 0.34 J,lg/ml in the
thalamus, 0.38 ± 0.24 J,lg/ml in the pre-central gyrus and 0.36 ± 0.16 J,lg/ml in
the frontal lobe. The absence of immunolabeled PK in the choroid plexus and
cerebellum is not fully understood. It is not always possible to obtain
conclusive correlation using different techniques. The ELlSA method is more
sensitive than the ICC method since it greatly enhances detection by the use
of specific conjugates such as horse radish peroxidase. In addition, the severe
fixation and labeling procedures of these tissues for ICC could result in
degradation of proteins, ultimately resulting in a lower detection signal.
The other main serine protease of the KKS, TK has previously been
demonstrated in various regions of the rat brain by specific radioimmunoassay
techniques using sheep anti-rat urinary kallikrein antiserum (Chao et al.,
1987). Subsequent studies immunolocalised TK in neurons of the
hypothalamus, thalamus, cerebral grey matter, reticular areas of the brain
stem, cells of the anterior pituitary and in epithelial cells of the choroid plexus
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in human brain (Raidoo et al., 1996). TK mRNA has been detected in the rat
brain using a TK cDNA probe (Chao et al., 1987) as well as in neurons of the
human hypothalamus and thalamus, in ependymal cells lining the cerebral
ventricles, and in interstitial tissue cells of the choroid plexus by in situ
hybridisation (Raidoo, 1999). The presence of immunoreactive PK in neurons
of the various brain regions and spinal cord, as well as in ependymal cells,
suggests that PK, via the generation of 8K, may be implicated in
neurophysiological processes. Further, we speculate that immunolabeling in
the myelinated fibre tracts of the pons, medulla and hippocampus may be due
to PK reacting with axonal proteins, the actual function of which remains to be
elucidated.
82 receptors are known to occur in animal neural tissue (Steranka et al.,
1988), primary brain cultures (Robert and Gulick, 1989), neuronal cell lines
(Snider and Richelson, 1984) and in neurons of the human cerebral cortex,
hypothalamus, thalamus and brain stem (Raidoo and 8hoola, 1997). In
addition, 82 receptor mRNA was found to be expressed in total human brain
extracts (Hess et al., 1992). Immunolabeling for 81 receptors have been
observed in neurons of the human hypothalamus, thalamus and spinal cord,
<
where it appears to modulate the cellular actions of kinins in neural tissue
(Raidoo and 8hoola, 1997). The presence of PK and both 81 and 82
receptors in the hypothalamus, thalamus and spinal cord suggests that the
PKKS may play a receptor-mediated role in pain modulation. However, this
needs to be elucidated by further studies to demonstrate PK expression in
specific areas involved in pain perception such as the thalamic somato-
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sensory relay and intralaminar nuclei, and the dorsal horn of the spinal cord.
The localisation of both PK and B2 receptors in the various regions of the
cerebral cortex (viz. frontal lobe, occipital lobe, pre-central and post-central
gyri) and brain stem (viz. medulla, pons and midbrain) indicates that the
cellular actions of the PKKS may be mediated by B2 receptors in these areas.
TK processes neuronal growth factors that maintain the integrity of
neurotransmitters and synaptic function (Bhoola et al., 1992). Jones et al.
(1992) demonstrated the presence of immunoreactive TK in prolactin-
secreting cells of the normal anterior pituitary gland as well as in prolactin-
secreting adenomas. Furthermore, it appears that TK may play an important
role in pituitary physiology and could also be involved in the intracellular
processing of prolactin prior to secretion (Jones et al., 1992). Since the
pituitary gland orchestrates the endocrine system via hormone synthesis and
secretion, the presence of immunoreactive PK in these secretory cells
suggests involvement in hormonal regulation probably by precursor activation.
A further function may be the regulation of cell proliferation since epidermal
and other growth factors are known to occur in the pituitary gland. PK
concentration, determined by ELlSA, was 0.36 ± 0.13 in pituitary gland
extracts.
Recently kininogen mRNA was shown to be expressed in cultures of rat
meningeal cells from the leptomeninges/choroid plexus which propose that
they are a major source of kininogens in rat brain (Takano et al., 1999). PK
measured by ELlSA in the choroid plexus (0.30 ± 0.15 Ilg/ml) may cleave HK
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to release BK, which would subsequently be transported via CSF throughout
the brain. We speculate that the PKKS may be endogenous in specific brain
area/s, on stand-by, until the onset of cerebral inflammation or injury, upon
which time it will be circulated upon demand to the affected brain areas.
4.10 Regulation of the PKKS in cerebral disease
Maier-Hauff et al. (1984) postulated that in pathological conditions such as
cerebral contusion, focal ischaemia and tumours activation of the PKKS may
occur resulting in damage to the blood brain barrier. A recent study in male
patients showed that during the acute stage of schizophrenia, there is an
associated increased activity of the PKKS, due to enhanced functional activity
of the o.t-proteinase inhibitor (Shcherbakova et al., 1999). Kinins also appear
to be implicated in Alzheimer's disease. Amyloid beta-(1-40) was found to
stimulate cyclic GMP production via the release of kinins in endothelial cells in
vitro; demonstrated by a 3-4 fold increase of kinins in the supernatants of
these cells; in addition cyclic GMP production was inhibited by both icatibant
as well as a novel selective PK inhibitor, Pefabloc PK (Wirth et al., 1999).
Numerous possibilities exist for antagonists to inhibit the PKKS. Specific sites
of inhibition could include Factor XII (by C1 esterase inhibitor or antithrombin
Ill) since it activates PK; PK (by C1 esterase inhibitor, u2-macroglobulin,
antithrombin III or Pefabloc PK); and HK, since it is the preferred substrate for
PK resulting in BK generation. The cellular actions of BK could be inhibited by
B1 receptor antagonists such as B-9224 and by the potent B2 receptor
antagonist, icatibant. Kininases that regulate the rate of formation and
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destruction of kinins (Erdos, 1989; Erdos, 1990) could also be manipulated to
allow for the control of kinin levels by selective enzyme inhibitors such as
captopril for KII-ACE, phosphoramidon for KII-NEP, and puromycin, amastatin
or bestatin for aminopeptidases (Bhoola et al., 1992).
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